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ABSTRACT
EFFICACY OF DEFERASIROX IN PREVENTING COMPLICATIONS OF IRON
OVERLOAD IN THE IRON OVERLOADED GERBIL
By Rabaa M. Al-Rousan
Iron overload is a significant, world-wide problem that results in several
chronic diseases including cardiovascular, hepatic and pancreatic complications.
The newly developed, orally effective, iron chelating agent deferasirox is thought
to offer tremendous promise as an alternative to deferoxamine. However, the
efficacy and safety profile of deferasirox is not yet clear. In the present study, the
efficacy of deferasirox in removing iron from target tissues has been examined
using the gerbil model of iron overload.
Deferasirox administration resulted in a significant reduction of iron from
cardiac and hepatic tissue. In addition deferasirox reduced iron induced increase
in cardiac and hepatic oxidative stress indices including ferritin expression,
superoxide production, protein oxidation, and ERK1/2, P38, and JNK
phosphorylation. These results indicate that deferasirox is capable of attenuating
iron- induced oxidative stress. Continuing our investigation we observed that iron
overload was also associated with an increase in hepatic cell death and
upregulation of Bax/Bcl-22, Bad expression, and caspase-3 cleavage. These
levels were significantly lower with deferasirox treatment suggesting a protective
role against cell death.
The primary overall goal of managing iron overload is to reduce/prevent
cardiac or other organ complications. In the present study we examined the
effect of iron overload on cardiac remodeling and functional parameters, and the
-ii-

effectiveness of chronic deferasirox administration to prevent or reduce these
changes using electro- and echocardiographic procedures. Compared to control,
iron overload was associated with left ventricular remodeling, arrhythmia, valve
regurgitation, and a decline in cardiac function.

These changes were highly

preserved with deferasirox treatment.
Following the preceding studies, we demonstrated a reduction in tissue
iron with deferasirox treatment in the iron overloaded gerbil model. The findings
of the present report established for the first time that deferasirox treatment is
capable of attenuating iron-induced increase in oxidative stress indices, tissue
ferritin protein expression, cell death, and more importantly, iron related
cardiovascular alterations. These findings suggest that deferasirox may be useful
in protection against iron-induced organ damage. The present report also
provides data elaborating on the possible mechanism by which iron overload
contributes to cellular injury, thereby allowing the development of better
therapeutic regimens to control this disorder.
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CHAPTER I
INTRODUCTION

Iron represents a paradox for living systems as it is essential for a wide variety of
metabolic processes, but also toxic if in excess. Iron is an indispensable constituent of
living cells and organisms due to its involvement in fundamental functions, which,
among others, include oxygen transport, transfer of electrons in the respiratory chain
and DNA synthesis (Ponka 1999). The chemical basis underlying the versatility of iron
for use in such crucial functions is provided by its unique ability to serve as both an
electron donor and acceptor, thus representing a potential partner in redox reactions.
However, this fundamental chemical property also is the basis of its toxicity, which
poses a threat when iron is present in excess or in non-protected forms (Eaton and
Qian 2002). Thus, organisms were compelled to solve one of the many paradoxes of
life, that is, to keep "free iron" at the lowest possible level through the evolution of
specialized molecules for the acquisition, transport, and storage of iron in a soluble,
nontoxic form to meet cellular and organismal iron requirements. Moreover, organisms
are equipped with highly sophisticated mechanisms that coordinately regulate cellular
iron uptake and storage and maintain iron in the intracellular labile pool at appropriate
levels (MacKenzie, Iwasaki et al. 2008).
Under conditions of iron overload this tight regulatory mechanism is disrupted
resulting in the accumulation of iron in toxic levels (Hershko, Link et al. 1998). Iron
overload can result from both primary and secondary causes. Primary iron overload
(hereditary hemochromatosis) results from genetic disorders of iron metabolism that
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cause excessive absorption of iron from the diet or deficient iron transport within the
body. Secondary iron overload results from factors that bypass normal iron metabolic
pathways, such as multiple blood transfusions (transfusional iron overload), or acute or
chronic iron poisoning (Kushner, Porter et al. 2001). As transfusion therapy for chronic
anemias and medical care has become more widely used, iron overload has become
increasingly more common (Wood, Skoien et al. 2009). Indeed, it is estimated that in
excess of two million individuals in the United States and up to one hundred million
humans worldwide acquire some degree of iron overload and tissue accumulation of the
metal (Hahalis, Alexopoulos et al. 2005).
Iron toxicity occurs when the amount of circulating iron exceeds the amount of
transferrin available to bind it forming non-transferrin bound iron (NTBI) (Andrews
2005). NTBI enters the cell at a high rate through a transferrin receptor-independent
pathway leading to iron accumulation in metabolically active tissues such as the liver,
heart, and pancreas (Hershko 2007). If left undiagnosed or untreated, excess iron in the
body is likely to cause cumulative toxicity which can lead to heart failure, hepatic
cirrhosis, and diabetes mellitus (Kohgo, Ikuta et al. 2008).
The mechanism(s) for iron mediated cellular injury are not clear, However, the
formation of the highly toxic hydroxyl radical via the Fenton reaction has been
suggested to be involved. Hydroxyl radical and other iron-mediated reactive oxygen
species (ROS) induce protein oxidation, lipid peroxidation, and DNA damage resulting
in loss of normal cellular functions (Galaris and Pantopoulos 2008). Iron is also
inhibitory to the proper functioning of ion channels including L-type calcium channels,
ryanodine sensitive calcium channels, fast-sodium channels, as well as the rectifier
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potassium channels, which can lead to the development of arrhythmias and poor
cardiac function in iron overload conditions (Wood, Enriquez et al. 2005).
As the human body has no inherent mechanism to remove excess iron, iron
chelating agents are used to treat iron overload. The goal of iron chelation therapy is to
remove the amount of iron accumulated and, as required, to reduce the existing iron
burden (Hershko, Link et al. 2005; Cianciulli 2008). To date, only deferoxamine is
globally available for the first-line treatment of transfusion-related iron overload. While
deferoxamine is effective, its administration is burdensome as it requires overnight
subcutaneous infusions for 5-7 nights/week. As such, many patients do not undergo
iron chelation therapy, exposing themselves to the dangers of iron overload (Chaston
and Richardson 2003). Deferiprone has been used for approximately 20 years and is
approved in Canada and Europe as a second-line therapy for patients unable to receive
deferoxamine or for those in which deferoxamine is less effective (Victor Hoffbrand
2005).

Although administered orally, the short half live of deferiprone necessitates

multiple daily oral doses for effectiveness. Like deferoxamine, deferiprone therapy is
also problematic as it is associated with serious toxic side effects including
transaminase increase, joint problems, severe neutropenia, and rare but life threatening
agranulocytosis (Kontoghiorghes, Neocleous et al. 2003). Further, because three
molecules of deferiprone are required to bind one molecule of iron, the ability of
deferiprone to adequately control body iron burden for long periods of time (4-6 years) is
questionable. Studies have demonstrated that liver iron levels are not as well controlled
with deferiprone as with deferoxamine, with liver iron levels remaining at levels above
the threshold associated with systemic complications (Kontoghiorghes, Neocleous et al.
2003).
-3-

Despite dramatic gains in life expectancy with deferoxamine chelation therapy,
the leading cause of death for iron overload patients remains cardiac disease from
cardiac iron deposition (Neufeld 2006). Strategies to reduce cardiac disease by
improving chelation regimens have been of the highest priority. These strategies have
included development of novel oral iron chelators to improve compliance, improved
assessment of cardiac iron status, and careful epidemiologic assessment of outcomes
with the current chelation regimens (Hider and Zhou 2005; Taher, Hershko et al. 2009).
As a result of these efforts, the novel oral chelator deferasirox was recently approved by
the Food and Drug Administration (FDA) for treatment of chronic iron overload in
transfusion dependent patients and is the first oral medication approved in the United
States for this purpose (Lindsey and Olin 2007; Stumpf 2007).
Unlike deferoxamine, deferasirox is a long acting, orally effective iron chelating
agent with favorable patient satisfaction (Neufeld 2006; Cappellini and Pattoneri 2009).
Deferasirox is a novel rationally designed iron chelator that has been selected from
more than 700 compounds (Cappellini and Piga 2008). It represents a new class of
tridentate iron chelators with a high specificity for iron (Cario, Janka-Schaub et al.
2007). Deferasirox possesses oral activity with around 70% bioavailability and long
plasma half life (8 to 16 hours) allowing once daily dosing. Deferasirox is well tolerated
as it is associated with relatively few side effects and a favorable pharmacokinetic
profile (Stumpf 2007). As such, deferasirox is expected to greatly enhance the
acceptance of iron chelation therapy, especially for children, and offers a new
alternative to the burdensome continuous infusion therapy. However, due to the limited
information regarding its effectiveness in removing tissue iron, deferasirox is less
frequently prescribed and is only available through specialty pharmacies where patients
-4-

have limited access to the medication. Deferoxamine has been the mainstay of iron
chelation therapy and still remains the most commonly used for the control of iron
overload conditions (Vichinsky, Pakbaz et al. 2008). It is clear that there is a critical lack
of information regarding several aspects of deferasirox therapy including whether or not
deferasirox is protective against iron-induced cardiac complications. This latter point is
important as this information is crucial to establishing the efficacy and safety profile of
deferasirox for fully justified use in human iron-overload therapy.
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PURPOSE

To date, only one investigation has examined the efficacy of deferasirox in
removing tissue iron in the gerbil model (Wood, Otto-Duessel et al. 2006). The effect of
deferasirox treatment on cellular indices of oxidative stress and iron-related cardiac
complications is not known. To address these gaps in our understanding, the purpose of
this research project was to examine: i) whether deferasirox is effective in removing iron
from target tissues and whether iron removal, if present, is associated with the reduction
of iron overload-related cell injury, and ii) whether deferasirox treatment can reduce or
prevent cardiovascular complications associated with iron overload. It is anticipated that
the outcomes derived from this study will be invaluable for understanding the efficacy
profile of deferasirox and will contribute important insight into the nature of the
protective mechanism(s) involved.
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SPECIFIC AIMS

Iron overload is an increasing worldwide problem associated with serious
complications. The present standard of care for iron overload is iron chelation by
deferoxamine; however, the use of this treatment is burdensome, invasive and thus
associated with low patient adherence (Brittenham 2003). The new iron chelating agent
deferasirox is thought to offer tremendous promise as an alternative to deferoxamine
(Olivieri and Brittenham 1997; Franchini 2005; Cappellini and Taher 2008). A review of
the scientific literature, however, demonstrates that the efficacy and safety profile of
deferasirox is not yet clear (Porter, Taher et al. 2008; Vichinsky 2008). Specifically,
information regarding the ability of deferasirox to protect against iron induced
cardiovascular alterations is lacking. This is important as it limits the utilization of a
potentially useful medication. The long-term goals are to improve our understanding of
deferasirox efficacy and safety in an endeavor to help improve the quality of life of
patients with iron overload. This study aims to firstly, determine whether deferasirox is
capable of removing iron from target tissues and reduce oxidative stress associated
with iron overload and secondly, to determine whether deferasirox is protective against
iron overload-induced cardiovascular alterations. These goals will be accomplished by
the following specific aims.

SPECIFIC AIM I: To determine if deferasirox is able to reduce cardiac iron
content, iron-induced ferritin upregulation, and iron-related increases in indices
of oxidative stress such as superoxide overproduction, protein oxidation, and the
phosphorylation of the mitogen activated protein kinase (MAPK) proteins
-7-

extracellular signal regulated kinase 1/2 (ERK1/2)-, p38-, and c-Jun N-terminal
kinase (JNK).

SPECIFIC AIM II: To determine if deferasirox is able to reduce hepatic iron
content, iron-induced ferritin upregulation, and iron related increases in indices of
oxidative stress and the effect of these changes, if present, on the incidence of
iron-related changes in cell death and apoptotic signaling.

SPECIFIC AIM III: To determine the long term cardiovascular complications
associated with iron overload and to determine if chronic deferasirox
administration is able to prevent/reduce these complications including those
related to cardiac remodeling and functional abnormalities.
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CHAPTER II
REVIEW OF THE LITERATURE

The following chapter presents a review of the pertinent literature concerning the
present study.

Specifically, the following areas will be addressed:

Body iron

homeostasis, disorders of iron overload, mechanisms of iron mediated toxicity, methods
of detecting body iron, management of iron overload, and animal models of iron
overload.

2.1 BODY IRON HOMEOSTASIS
2.1.1 Normal distribution of body iron stores
The total amount of iron in the human body is approximately 3-4 g (Andrews
2005). The vast majority of body iron (about 2.5 g) is contained in hemoglobin. A
significant portion of iron (~ 400 mg) is devoted to cellular proteins that use iron for
important cellular processes like storing oxygen (myoglobin), or performing energyproducing redox reactions (cytochromes). Approximately 3-4 mg circulates in the
plasma as an exchangeable pool bound to transferrin. This chelation serves three
purposes: it renders iron soluble under physiologic conditions, it prevents iron-mediated
free radical toxicity, and it facilitates transport into cells (MacKenzie, Iwasaki et al.
2008). The sum of all iron binding sites on transferrin constitutes the total iron binding
capacity (TIBC) of plasma. Under normal circumstances, about one-third of transferrin
iron-binding pockets are filled and non-transferrin-bound iron in the circulation is virtually
nonexistent.
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Physiologically, most stored iron (~1g) is bound by ferritin molecules; the largest
amount of ferritin-bound iron is found in hepatocytes, bone marrow, and spleen (Lash
and Saleem 1995). Of these, the liver is considered the primary physiologic source of
reserve iron in the body. Reticuloendothelial cells store iron as part of the process of
phagocytosis and breakdown of aging red cells. These cells extract iron from heme and
return it to the circulation bound to transferrin (Andrews and Schmidt 2007). There is no
specific physiological mechanism for iron excretion from the body and thus the amount
of body iron is controlled by the rate of its absorption by duodenal enterocytes. On a
daily basis, adult humans absorb 1–2 mg of iron from the diet to compensate for nonspecific iron losses such as that which occurs following desquamation or blood loss
(Donovan, Roy et al. 2006).
2.1.2 Regulation of iron absorption
It is thought that the first step of iron absorption involves the reduction of Ferric
iron Fe(III) in the intestinal lumen by ferroreductase Dcytb (duodenal cytochrome b), to
the more soluble form Fe(II) (Pantopoulos 2004). Ferrous iron Fe(II) is then transported
across the basolateral membranes of the enterocytes by divalent metal transporter 1
(DMT1) (Figure 1, Panel A). The export of Fe(II) across the basolateral membranes of
enterocytes to circulation is mediated by ferroportin. This step is coupled with
reoxidation of ferrous to ferric iron by membrane-bound hephastin (or its plasma-soluble
homologue ceruloplasmin) (Donovan and Andrews 2004; Pantopoulos 2004). Plasma
iron is immediately scavenged by the plasma iron carrier transferrin (Tf) in 2:1 ratio.
Plasma Tf binds to its cell surface receptor (TfR) and the complex is internalized by
endocytosis. Acidification of the endosomes results in the release of ferric iron from Tf
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and reduction and subsequent transport of ferrous iron across the endosomal
membranes by DMT1. The pathway is completed by recycling of the apo Tf-TfR
complex to the cell surface and release of apoTf which is transported back to the
circulation to carry new iron ions (Figure 1, Panel B).

Figure 1. (A) Schematic representation of iron transport across duodenal
epithelial cells. (B) Cellular iron uptake from transferrin (Tf) via receptor
mediated endocytosis. (Pantopoulos 2004)
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Following its release from transferrin within endosomes, iron is thought to enter
the labile iron pool (LIP) where it becomes available for intracellular use or for storage in
ferritin (Andrews 2008). Another source of iron for this pool comes from the breakdown
of nonheme- and heme- iron-containing proteins. It has been proposed that iron in this
pool may form complexes with citrate, sugars, various amino acids, pyridoxal, or
nucleotides, but the details regarding the regulation of this pool remain elusive (Kakhlon
and Cabantchik 2002).
2.1.3 Regulation of systemic iron homeostasis
Iron homeostasis in mammals is regulated at the level of intestinal absorption, as
there is no excretory pathway for iron. Hepcidin, a circulating peptide hormone, is the
master regulator of systemic iron homeostasis, coordinating the use and storage of iron
with iron acquisition (Hershko 2006). This hormone is primarily produced by
hepatocytes and is a negative regulator of iron entry into plasma (Sela 2008). Hepcidin
acts by binding to ferroportin, an iron transporter present on cells of the intestinal
duodenum, macrophages, and cells of the placenta (Ramey, Deschemin et al. 2009).
Binding of hepcidin induces ferroportin internalization and degradation resulting in
reduced iron entry into plasma. Conversely, decreased expression of hepcidin leads to
increased cell surface ferroportin and increased iron absorption. Plasma hepcidin levels
are regulated by different stimuli, including cytokines, plasma iron, anemia, and hypoxia
(Ganz 2003; De Domenico, Ward et al. 2007). Overexpression of hepcidin has been
linked to the development of anemia, while low hepcidin is associated with hereditary
hemochromatosis (De Domenico, Ward et al. 2007).

-12-

2.1.4 The IRP-IRE regulation of cellular iron homeostasis
The iron-responsive element, (IRE), is present in the mRNA of various iron
regulatory proteins including ferritin and the transferrin receptor. Enlargement of the
intracellular transit iron pool, in general, leads to a stimulation of ferritin synthesis and
decrease in the expression of transferrin receptors (Pantopoulos 2004).
Iron-dependent regulation of both ferritin and transferrin receptors is mediated by
virtually identical IREs. The IREs are hairpin structures recognized by iron-regulatory
protein-1 (IRP1). When cellular iron becomes limiting, the IRP-1 becomes bound to the
IRE located within the 5' UTR of the ferritin mRNA and this represses the translation of
ferritin (Figure 2, upper panel). A similar mechanism regulates the expression of
transferrin receptor. Under conditions of low iron, IREs within the 3' UTR of the
transferrin receptor mRNA become bound by IRP-1, which in turn stabilizes the
transcript against ribonuclease activity (Figure 2, lower panel). Together, these
responses lead to increased iron uptake and reduced iron storage. Conversely, the
expansion of the labile iron pool inactivates IRP-1, resulting in an efficient translation of
ferritin mRNA and rapid degradation of transferrin receptor mRNA. These responses
lead to decreased iron uptake and elevated iron storage (Ponka 1999; Munoz, Villar et
al. 2009).
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Figure 2. Role of cellular iron level in the regulation of ferritin and transferrin
receptor expression via the IRE/IRP system. (Ponka 1999)

2.2 DISORDERS OF IRON OVERLOAD
Iron overload is a group of disorders caused by the accumulation of iron in the
body. These disorders can be either acute or chronic in nature (Heeney and Andrews
2004). Acute iron overload is typically caused by excess iron intake such as that seen
after the accidental ingestion of large quantities of iron-containing multivitamins, or iron
supplements in young children. Acute iron overload has been found to irritate the
stomach lining, and is associated with nausea and vomiting. If the intake is excessive,
damage to internal organs (e.g. brain and the liver), metabolic acidosis and death
oftentimes result (Singhi, Baranwal et al. 2003). In contrast to that observed for acute
iron overload, the manifestation of chronic iron overload appears to be more varied as
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this disorder can be caused by primary (genetically determined) conditions or arise
secondary to other conditions (Piperno 1998).
2.2.1 Primary iron overload (Hereditary hemochromatosis)
Hereditary hemochromatosis is caused by mutation of genes involved in
regulation of iron homeostasis (Table 1). The majority depend on defined- HFE gene
mutations discovered in 1996 and are referred to as “classical hemochromatosis”
(Janssen and Swinkels 2009).

Table 1. Hereditary hemochromatosis; Classification and associated gene products
Classification

Associated gene product

Type I: "classical" hemochromatosis HFE
Type IIA: Juvenile hemochromatosis

Hemojuvelin “HJV”

Type IIB: Juvenile hemochromatosis

Hepcidin antimicrobial peptide “HAMP”

Type III

Transferrin receptor-2 “TFR-2”

Type IV: African iron overload

Ferroportin

Neonatal hemochromatosis

Unknown

Aceruloplasminemia

Ceruloplasmin

Congenital atransferrinemia

Transferrin

GRACILE syndrome

BCS1L
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Other gene mutations have been discovered later and are grouped together as
"non-classical hereditary hemochromatosis" or "non-HFE hemochromatosis". Most
types of hereditary hemochromatosis have autosomal recessive inheritance, while type
IV has autosomal dominant inheritance (Janssen and Swinkels 2009).
While the genetic mutations causing several variants of hemochromatosis have
been identified, the exact function of these genes is yet unknown. However, most
genetic forms of iron overload seem to be associated with hepcidin deficiency resulting
in increased intestinal absorption of iron (Lee and Beutler 2009). An exception is type IV
hemochromatosis where ferroportin becomes mutated resulting in a deficiency in the
action of hepcidin (Fernandes, Preza et al. 2009).
2.2.2 Secondary iron overload
Secondary iron overload may result from chronic blood transfusion, from
increased gastrointestinal absorption of iron, or from some combination thereof
(Kushner, Porter et al. 2001).
Chronic blood transfusion: An adequate transfusion program can sustain life in
patients with severe chronic refractory anemia, but transfusion therapy alone produces
a progressive accumulation of the iron contained in transfused red cells. In patients with
severe congenital anemias, such as thalassemia major and the Blackfan-Diamond
syndrome, regular transfusions can prevent death from anemia in infancy and permit
normal growth and development during childhood but, if left uncontrolled, may result in
severe iron overload by adolescence (Borgna-Pignatti, Rugolotto et al. 2004; Chen,
Tseng et al. 2009). Treatment of acquired transfusion-dependent anemias, such as
aplastic anemia, pure red cell aplasia, and hypoplastic or myelodysplastic disorders,
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among others, may also result in the development of marked iron overload (Malcovati
2009). In addition, although sickling disorders (e.g., sickle cell anemia) are not
transfusion-dependent, these patients may acquire a considerable iron load from
repeated transfusions for the prevention of stroke, painful crises, and other recurrent
complications (Ballas 2001).
About 200 to 250 mg of iron is added to the body iron load with each unit of
transfused red cells. Most transfusion-dependent patients require 200 to 300 ml/kg of
blood a year; for example, a 70 kg adult requires about two to three units of blood every
3 to 4 weeks, adding about 6 to 10 g of iron a year (Agarwal 2009). The severity of iron
toxicity seems to be related to the magnitude of the body iron burden. Almost all
patients who have been treated with transfusion alone and have received 100 or more
units of blood (about 20 to 25 g of iron) develop cardiac iron deposits, often in
association with signs of hepatic, pancreatic, and endocrine damage (Brittenham 2006)
Ineffective erythropoiesis: This disorder occurs in patients with congenital
dyserythropoietic anemia, pyruvate kinase deficiency, thalassemia major, thalassemia
intermedia, sideroblastic anemia, some myelodysplastic anemias, and other anemic
disorders in which the incorporation of iron into hemoglobin is impaired (Sarnaik 2005;
Rivella 2009). As a result of ineffective erythropoiesis, plasma iron turnover increases
drastically, resulting in excessive production of growth differentiation factor 15 (GDF15)
(Tanno, Bhanu et al. 2007). GDF15 is a member of the transforming growth factor-β
(TGF-β) superfamily which, at high levels, is able to suppress hepcidin production,
resulting in increased intestinal iron absorption and release of catabolic iron from
macrophages (Gardenghi, Marongiu et al. 2007).
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Chronic liver disease: Some patients with chronic liver disease, for example
alcoholic cirrhosis, may experience minor or modest degrees of iron loading as a result
of increased dietary iron absorption (Schulz and Sanft 1984; Duane, Raja et al. 1992).
The mechanisms responsible for the increased gastrointestinal iron uptake have not
been identified, although ineffective erythropoiesis and hyperferremia associated with
alcohol-induced folate and sideroblastic abnormalities have been proposed as etiologic
factors (Gentry-Nielsen, Preheim et al. 2001; Harrison-Findik 2007). Body iron stores
are increased only to a minor degree, but in alcoholic cirrhosis, the higher the liver iron
the shorter the survival.
Focal sequestration of iron: Focal iron sequestration is found in rare disorders,
including idiopathic pulmonary hemosiderosis and renal hemosiderosis (Piperno 1998).
Such abnormal iron deposition is also associated with neurologic abnormalities
including Friedreich ataxia, in which decreased iron-sulphur-cluster and heme formation
leads to mitochondrial iron accumulation primarily in sensory neurons, myocardium and
endocrine glands (Boddaert, Le Quan Sang et al. 2007; Gucev, Tasic et al. 2009).

2.3 CLINICAL MANIFESTATION OF IRON OVERLOAD
Because humans lack a physiologic means of eliminating excess iron, iron
progressively accumulates and eventually damages the liver, heart, pancreas, and other
organs with death usually occurring as a result of cardiac failure (Hershko 2007). In
younger patients, the iron burden results in growth failure and, in adolescence, delayed
or absent sexual maturation (Nabavizadeh, Anushiravani et al. 2007; Safarinejad 2008).
The precise manifestations of iron overload, however, depend on different factors
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including, the underlying abnormality, body iron burden, the rate at which the increase in
body iron has occurred and the distribution of the excess iron between storage sites
(Kontoghiorghes, Pattichi et al. 2000; Wood, Skoien et al. 2009).
Initially, the deleterious effects of iron loading are not clinically significant, and
manifest as discomfort in hand joints, increased skin pigmentation and fatigue
(MacKenzie, Iwasaki et al. 2008). As tissue iron accumulates, liver damage ranging
from fibrosis to cirrhosis can develop in affected individuals. In hereditary
hemochromatosis, hepatomas develop almost exclusively in patients with hepatic
cirrhosis and are the ultimate cause of death in 20% to 30% of these patients
(MacKenzie, Iwasaki et al. 2008).
Iron overload also leads to iron deposition in the heart and endocrine tissues.
Chronically elevated cardiac iron concentrations impair diastolic function, increase the
propensity for arrhythmias, and, ultimately, cause end stage cardiomyopathy (Wood,
Enriquez et al. 2005). Iron overload cardiomyopathy, defined as the presence of systolic
or diastolic cardiac dysfunction secondary to increased iron deposition, is an important
cause of heart failure and is the primary determinant of survival in patients with iron
overload (Wood, Enriquez et al. 2005; Lekawanvijit and Chattipakorn 2009).
Cardiomyopathy develops initially as a severe diastolic dysfunction; in the later stages
however, heart failure progresses to severe systolic dysfunction and ventricular dilation.
Death ensues promptly in the later stages due to cardiac failure and/or severe
arrhythmias (Bartfay 1999). Other targets of iron deposition include pancreas (glucose
intolerance, diabetes), posterior pituitary gland (secondary hypogonadism), joints
(arthropathy), and neurons (neurological abnormalities) (Gamberini, De Sanctis et al.
2008) .
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2.4 MECHANISMS OF IRON MEDIATED TOXICITY
2.4.1 Formation of non-transferrin bound iron
Iron toxicity results when iron in the circulation exceeds serum transferrin ironbinding capacity, leading to the appearance of non-transferrin-bound iron (NTBI) (Eaton
and Qian 2002). The exact nature of NTBI is not clear, but it is believed to consist of
labile low-molecular weight complexes of iron with plasma components such as
albumin, citrate and phosphate (Cabantchik, Breuer et al. 2005). Unlike transferrin–
bound iron, NTBI enters cells via a transferrin receptor-independent mechanism and at
a rate exceeding the normal uptake of transferrin iron. NTBI uptake into cells bypasses
the normal negative feedback regulatory mechanisms that control cellular iron uptake
and metabolism. Once NTBI enters the cells, it is rapidly buffered by ferritin, limiting its
potential for redox damage or other harmful interactions in the cell (Wood, Enriquez et
al. 2005). Nonetheless, all buffering systems have limited capacity or can be disrupted
by other factors. Thus, excess uptake of NTBI, combined with the lack of an effective
iron excretory pathway, leads to the expansion of the labile intracellular iron pool (LIP),
resulting in the formation of highly-reactive oxygen free radicals (Kruszewski 2003;
Ozment and Turi 2009).
Ferritin molecules aggregate over time to form clusters, which are engulfed by
lysosomes and degraded (Iancu et al. 1977, Bridges 1987). The end-product of this
process, hemosiderin, is an amorphous agglomerate of denatured protein and lipid
interspersed with iron oxide molecules (Wixom et al. 1980). Although the iron enmeshed
in this insoluble compound constitutes an endstage product of cellular iron storage, it
remains in equilibrium with soluble ferritin. Ferritin iron, in turn, is in equilibrium with iron
complexed to low molecular weight carrier molecules (Konijn, Glickstein et al. 1999).
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Therefore the introduction into the cell of an effective chelator captures iron from the low
molecular weight "toxic iron" pool, draws iron out of ferritin, and eventually depletes iron
from hemosiderin as well, though only very slowly (Crichton and Ward 2003).
2.4.2 Chemistry of iron and ROSs
The initial reactive oxygen intermediate produced in most cases of oxidative
stress is superoxide (O2·−) (Turrens 2003). Cellular sources of O2·− include
mitochondria and lysosomes, with the production of this molecule exacerbated under
conditions of hypoxia or ischemia. Once formed, superoxide is rapidly converted to
H2O2 by the action of superoxide dismutases (SOD):

2O2·− + 2H+ → H2O2 + O2

Neither O2·− nor H2O2 are strong oxidizing agents, however when free iron ions are
available, Fenton-type reaction takes place (Galaris and Pantopoulos 2008), producing
the extremely reactive hydroxyl radical (·HO):

Fe2+ + H2O2 → Fe3+ + OH- + OH•

Superoxide anion may reduce Fe3+ back to Fe2+ (Haber-Weiss reaction), thus allowing
iron to act as an autocatalyst of the reaction (Kell 2009):

Fe3+ + O2·− → Fe2+ + O2
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In addition, Fe2+ and certain Fe2+ chelates react with lipid hydroperoxides (LOOH), as
they do with hydrogen peroxide, splitting the O–O bond. This gives rise to the alkoxyl
radical (LO·), which can also abstract H· from polyunsaturated fatty acids and from
hydroperoxides (Kell 2009):

LOOH + Fe2+ → OH- + LO• + Fe3+

Alternatively, Fe3+ can initiate the reaction with lipid hydroperoxides (LOOH). The
resulting peroxyl radicals (LOO·) can continue propagation of lipid peroxidation:

LOOH + Fe3+ → H+ + LOO• + Fe2+

Furthermore, elevated superoxide liberates free iron from ferritin, thereby
providing a positive feedback loop where the increase in the amount of free iron
catalyses the production of further hydroxyl radical formation (Keyer and Imlay 1996)
(figure 3).
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Figure 3. Catalysis and autocatalysis in the Haber-Weiss and
Fenton reactions leading to the production of the hydroxyl
radical, including the liberation by superoxide of free iron from
ferritin. (Kell, 2009)

2.4.3 Targets of iron-driven cellular damage
Given the tendency of transition metals such as iron to amplify oxidant damage,
the fact that organs with very active mitochondria are targeted in iron overload disorders
is probably no coincidence (Eaton and Qian 2002). The liver and heart have high
steady-state production of O2·− and H2O2, largely derived from mitochondrial activity
(Han, Williams et al. 2001). The pancreatic beta cell is also rich in mitochondria and is
highly sensitive to oxidant-generating substances (Maiese, Chong et al. 2007).
However, although the hepatic, cardiac, and pancreatic beta cell pathologies caused by
iron overload probably involve an iron-driven oxidative component, the precise
mechanisms through which reactive iron conspires with oxygen to amplify cellular
oxidant damage remain unknown. The fundament of iron-mediated oxidant damage
may be the tendency of free iron to associate with oxidizable targets within cells (e.g.,
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polyunsaturated fatty acids, proteins, or DNA) and to engage in site-specific oxidation
reactions (Lucesoli and Fraga 1995). These latter reactions have often been ascribed
to the hydroxyl radical but more likely represent multiple reactions arising from
complexes of iron bound to particular target molecules and oxidants which, upon
reaction with the iron, form a highly oxidizing intermediate (ferryl or perferryl) (Eaton and
Qian 2002).
Iron catalyzes the production of free radicals which can directly interact with
many biological macro- and small molecules, leading to oxidative membrane damage
throughout the cell (Galaris and Pantopoulos 2008). Excessive free radical generation
leads to increased lipid peroxidation, protein oxidation, and gene modulation, triggering
cellular damage and antioxidant depletion (Livrea, Tesoriere et al. 1996; Brown, Kinter
et al. 1998; Bartfay, Dawood et al. 1999). Metal-catalyzed damage to proteins includes
loss of histidine residues, bityrosine cross links, oxidative scission, the introduction of
carbonyl groups (through, e.g., oxidative deamination), and the formation of proteincentered alkyl, alkylperoxyl, and alkoxyl radicals (Valko, Rhodes et al. 2006).
Polymerization and denaturation of proteins and proteolipids form insoluble structures
typically known as lipofuscin (Kell 2009). Elevated cellular iron levels also leads to DNA
damage. Products of reactions between DNA, iron, and oxidants are not yet fully
elucidated but include strand breaks, oxidatively modified bases, and DNA protein
cross-links (Meneghini 1997; Gao, Campian et al. 2009). The relative importance of all
these products in long-term iron-mediated DNA damage is not yet known. Alterations in
gene expression and gene modulation have also been reported (Barouki and Morel
2001; Parkes and Templeton 2003); however, whether these changes represent

-24-

controlled interactions through iron response elements or nonspecific effects from redox
damage is unclear.
Iron is preferentially taken up by mitochondria and lysosomes. In the
mitochondria, iron accumulation results in peroxidation of polyunsaturated fatty acids
(PUFA) within membrane phospholipids (Britton, O'Neill et al. 1990), disruption of
mitochondrial respiratory enzymes (Bacon, O'Neill et al. 1993; Link, Saada et al. 1998)
and mitochondrial DNA damage (Gao, Campian et al. 2009). Accumulation of iron within
the cellular lysosomal compartment will sensitize the lysosomes to damage and rupture
with release of damaging lysosomal digestive enzymes into the cytoplasm of the cell
(Stal, Glaumann et al. 1990). Minimal release of lysosomal enzymes may induce
transient reparative autophagocytosis, while moderate lysosomal rupture is followed by
caspase activation and apoptosis (Kurz, Terman et al. 2008). Severe oxidative stress,
resulting in massive lysosomal breakdown, is associated with necrosis (Kurz, Terman et
al. 2008).
Iron can also directly interact with ion channels. For example, ferrous iron has
similar size and charge to that of calcium ions and can permeate through cardiac L-type
calcium channels (LTCC) (Oudit, Sun et al. 2003). Fe2+ slows Ca2+ current inactivation
resulting in increase in the time integral of the Ca2+ current and net Ca2+ influx, which
may possibly contribute to the impaired diastolic function observed during the early
stages of iron overload

(Oudit, Trivieri et al. 2006). With higher concentrations of

ferrous iron there is a reduction in Ca2+ current due to competition with ferrous iron. This
may contribute to the systolic dysfunction that is characteristic of more advanced ironoverload cardiomyopathy (Oudit, Trivieri et al. 2006) . Ferrous iron can also directly
interact with the ryanodine sensitive calcium channel in the sarcoplasmic reticulum
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(Kim, Giri et al. 1995). This channel is responsible for activation of contraction and also
modulates calcium reuptake in the sarcoplasmic reticulum.
In addition to its effects on calcium homeostasis, intracellular iron impairs the
function of membrane-bound fast-sodium channels as well as delayed rectifier
potassium currents (Wood, Enriquez et al. 2005). The former channels are responsible
for the rapid upstroke of the cardiac action potential. Channel blockage or other
interference will slow cardiac conduction, and delay action potential spread across the
myocardium (Wood, Enriquez et al. 2005). Hence it is not surprising that iron overload
results in arrhythmias and poor cardiac function.

2.4.4 ROS and iron-mediated intracellular signaling
Mammalian cells exhibit a broad spectrum of responses toward oxidative stress,
which is dependent on the severity of the stress encountered and the availability of
catalytically active iron (Deb, Johnson et al. 2009). The members of mitogen-activated
protein kinases (MAPKs), including ERK, JNK, and p38 subfamilies, have all been
shown to be activated in response to oxidant injury and therefore could potentially
contribute to influencing cell survival (Griendling, Sorescu et al. 2000). Each MAPK
subtype is activated by phosphorylation on threonine and tyrosine residues by upstream
dual-specificity kinases. In general, the ERK cascade appears to mediate signals
promoting cell proliferation, differentiation or survival, whereas the p38 and JNK
cascades appear to be involved in the cell responses to stresses (Martindale and
Holbrook 2002). However, activation of distinct MAPK subtypes is dependent on the cell
type and the stimuli. It was recently suggested that iron loading in vitro induces p38 and
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ERK 1/2 phosphorylation associated with an increase in ROS levels (Antosiewicz,
Ziolkowski et al. 2007).
Ferritin represents the main iron storage protein, and its concentration is mutually
related with the cytosolic level of labile iron. Changes in iron availability regulate ferritin
expression primarily at the translational level through specifically regulated protein-RNA
interactions between IRPs and IREs as described earlier in this chapter. In iron overload
conditions, serum ferritin expression is increased, which is used as one common
diagnostic tool to reflect body iron status (Piperno 1998).
Other pathways that are clearly linked to ROS include the induction of
programmed cell death (apoptosis) (Orrenius 2007). Apoptosis is a genetically
controlled response to eliminate unwanted cells that is involved in the regulation of cell
number under several physiological and pathological conditions. High levels of ROS can
lead to necrotic cell death, whereas low levels of ROS have been shown to induce
apoptotic cell death (Denecker, Vercammen et al. 2001). Apoptosis is regulated through
different mechanisms, including the expression of the members of the Bcl-2 protein
family consisting of pro- and anti-apoptotic peptides interacting with each other by
forming homo- and heterodimers. Bcl-2 is thought to act as negative regulator of
apoptosis and has been thought to protect cells from ROS (Li, Ueta et al. 2004),
although the mechanism by which this latter event occurs remains unclear. Conversely,
Bax has been implicated to promote or accelerate cell death with recent data showing
that Bax may be able to induce apoptosis by both caspase-dependent and -independent
mechanisms. Recent studies have suggested that iron induces cell apoptosis via the
promotion of Bax translocation, cytochrome c release, and caspase-3 activation (Yajun
2005). Whether iron exerts its signaling effects independently or it simply participates in
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reactions of ROS-mediated signaling is presently unknown and needs further
investigation.

2.5 METHODS OF DETECTING BODY IRON
Both direct and indirect means for the assessment of body iron are available but
no single indicator or combination of indicators is ideal for the evaluation of iron status in
all clinical circumstances. As 90% of excess iron is deposited in the liver, measurement
of hepatic iron stores provides the most quantitative means of assessing the body iron
burden and may be considered the reference method for comparison with other
techniques (Vermylen 2008). The invasive nature of the liver biopsy, however, means
that other markers such as serum ferritin levels are frequently employed. Other
approaches using biomagnetic susceptometry and magnetic resonance imaging (MRI)
are also being assessed in order to identify an accurate, low-risk, and convenient
approach to assessing patient iron status.

2.5.1 Indirect Assessment
Serum ferritin: Serum ferritin is easily measured using a commercially available
kit. A ferritin level constantly below 2500 µg/L has been shown to reduce the risk of
cardiac complications, but a target value of 1000 µg/L is recommended. Factors such as
inflammation, ascorbate status, and hepatitis can affect serum ferritin levels (Olivieri, De
Silva et al. 2000). Therefore, results should be interpreted with caution and a trend in
the evolution of serial measurements is a better index than day-to-day variation. In
patients with transfusion-dependent diseases, chelation should be initiated after 10–20
blood transfusions or when ferritin level rises above 1000 µg/L (Vermylen 2008).
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24–hour deferoxamine-induced urinary iron excretion:

This includes

measuring the amount of chelated iron in the urine after a single intramuscular dose or
prolonged subcutaneous infusion of deferoxamine. The usefulness of this method has
several limitations in the accurate assessment of body iron burden (Olivieri and
Brittenham 1997). Most important is the poor correlation between urinary iron excretion
and hepatic iron concentration which develops, at least in part, because the relative
amounts of iron excreted into stool and urine vary with the dose of deferoxamine
administered, body iron burden, and erythroid activity (Olivieri and Brittenham 1997).
Chelator-induced urinary iron excretion is also vulnerable to extraneous influences by
infection, inflammation, the activity and effectiveness of erythropoiesis, extramedullary
hematopoiesis, liver disease, and ascorbic acid deficiency.

Magnetic resonance imaging (MRI): MRI measures tissue iron concentration
indirectly by detecting the paramagnetic influences of storage iron (ferritin and
hemosiderin) on proton resonance behavior. Iron deposits act like little magnets when
placed in a strong magnetic field, disrupting coherence among the emitted protons and
darkening the image more quickly (Vermylen 2008). Liver iron content (LIC) determined
using MRI shows excellent correlation with that obtained from liver biopsy
(Papakonstantinou, Maris et al. 1995). Furthermore, MRI has the ability to evaluate the
entire organ and gives more accurate measurement of LIC, particularly in patients with
heterogeneous iron content (Li, Aisen et al. 2004). Although very promising, the
widespread use of this method in many parts of the world may be hampered by the
need for expensive equipment and trained personnel to perform the scan.
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2.5.2 Direct assessment
Liver biopsy: The measurement of liver iron content is the most accurate
method for assessing body iron and thus it is referred to as the “gold standard” as there
is a high correlation between LIC and total body iron (Alustiza, Castiella et al. 2007).
The procedure also provides information about the severity of the liver disease. Liver
biopsy, however, is an invasive technique that is associated with some pain and risk of
hemorrhage and infection. Thus, it is not indicated for routine assessment.

Superconducting quantum interference device (SQUID): SQUID provides a
direct measure of tissue iron that is based on a fundamental physical property of ferritin
and hemosiderin (Olivieri et al, 1997). SQUID is capable of measuring very small
changes in magnetic flux. Iron stored as ferritin and hemosiderin is the only relevant
paramagnetic material in the human body. The magnitude of paramagnetic response is
directly related to the amount of iron in a certain volume of tissue (Vermylen 2008). This
is a noninvasive method, with a linear correlation with LIC assessed by biopsy.
However, equipment availability is extremely limited.

2.6 MANAGEMENT OF IRON OVERLOAD
Iron overload treatment is dependent on the underlying condition. Phlebotomy is
currently the recommended iron overload treatment for most patients with hereditary
excess iron, although iron chelation therapy could be an option for patients who cannot
or choose not to undergo phlebotomy (Brissot 2009). For transfusional iron overload,
iron chelation therapy is the first-line therapy (Cappellini 2005).
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2.6.1 Phlebotomy
The treatment of choice for hereditary hemochromatosis is phlebotomy to reduce
the body iron levels to normal or near-normal and maintain them in that range (Tavill
2001). In patients with hereditary hemochromatosis who develop cardiac failure, the use
of both phlebotomy and chelation therapy has been suggested. Phlebotomy therapy
should be started as soon as the diagnosis of the homozygous state for hereditary
hemochromatosis has been established, as postponement is likely to increase the risk
of organ damage from iron overload. The phlebotomy program should remove 500 ml of
blood (containing 200 to 250 mg of iron) once weekly or, for heavily loaded patients,
twice weekly until the patient is iron deficient (Brissot 2009).
In patients with hereditary hemochromatosis, prolonged treatment is often
needed. For example, if the initial body iron burden is 25 g, complete removal of the iron
burden with weekly phlebotomy may require 2 years or more. After the iron load has
been completely removed, a lifelong program of maintenance phlebotomy is required to
prevent reaccumulation of the iron burden (Tavill 2001). Typically, phlebotomy of 500 ml
of blood every 3 to 4 months is needed. If phlebotomy therapy removes the iron load
before diabetes mellitus or cirrhosis develops, the patient's life expectancy is expected
to be normal. If cirrhosis develops, however, the risk of hepatocellular carcinoma is
increased by more than 200-fold (Bacon 2001). Phlebotomy therapy is almost always
indicated for patients with hereditary hemochromatosis, even when cirrhosis or organ
damage is already present, as further progression of the disease can be stopped with
the possibility of minimizing organ dysfunction (Brissot 2009).
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2.6.2 Chelation therapy
For patients requiring regular blood transfusions, iron chelation may represent
life-saving therapy. In patients with thalassemia major, the availability of chelation
therapy led to one of the most marked improvements in morbidity and mortality
associated with a genetic disease (Cianciulli 2008; Agarwal 2009). The major goal of
iron chelation therapy is to bind NTBI and intracellular labile iron, thereby effectively
eliminating toxic iron (Porter 2007). Due to the cumulative nature of iron loading,
continuous (24-hour) control of NTBI levels is desirable (Ozment and Turi 2009).
Although the benefits of chelation therapy with regard to a reduction in morbidity
and mortality may be apparent within a much shorter timeframe, it may take years for
body iron levels to reach normal levels. The availability of effective iron chelation
therapies has significantly extended the life expectancy of transfusion-dependent
patients, and consistent therapy reduces the toxicity and organ damage associated with
excess iron (Cario, Janka-Schaub et al. 2007).
For any given patient, reaching their target body iron levels depends to a large
extent on their ability to comply with long-term therapy, which itself is largely determined
by the side effects, tolerability, perceived efficacy and convenience of the iron-chelating
agent (Cohen 2006). Unfortunately, the survival and health benefits of current iron
chelation agents decline measurably with even minimal reductions in compliance.
Therefore, optimal compliance requires that patients both understand the nature of the
threat of iron overload, and receive psychological and social support for continuing both
blood transfusions and iron chelation therapy (Cohen 1990).
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Three approved iron chelation agents are available currently: Deferoxamine,
deferiprone, and deferasirox, with the approval and availability of these agents largely
country specific (Cohen 2006). These three compounds are compared in table 2 to the
properties of an ideal chelator.
Deferoxamine (DFO)
DFO, a hexadentate siderophore (Figure 4) isolated from Streptomyces pilosus,
has been the clinical chelator of choice for the treatment of iron overload diseases since
the 1970s (Brittenham 2003). The high affinity of this siderophore for Fe(III) renders iron
bound in the resulting 1:1 complex metabolically inactive, preventing the production of
ROS. Consequently, DFO is able to decrease oxidative stress, alleviating the symptoms
associated with iron overload disease (Olivieri and Brittenham, 1997). However, the
DFO-iron chelate is charged and does not readily enter and leave cells. The high
hydrophilic nature of DFO limits the membrane permeability and efficiency of this ligand,
imparting poor absorption from the gastrointestinal tract and a short plasma half-life of
12 minutes due to rapid drug metabolism (Aouad et al. 2002). As a result, DFO must be
administered via subcutaneous infusion for extensive periods to achieve a negative iron
balance, ranging from 8 to 12 h, five to seven times per week at a daily dosage of 20 to
60 mg/kg (Hershko et al. 2003). Apart from the cumbersome administration route and
high cost, a third of patients treated with DFO experience pain and swelling at the
injection site, cumulatively leading to poor patient compliance (Olivieri and Brittenham,
1997; Wong and Richardson, 2003). Irrespective of its shortcomings, it should be noted
that DFO use has been credited with producing dramatic strides in survival of
thalassemia patients.

-33-

Given the potential problems associated with the prolonged use of DFO, there
have been numerous attempts to improve its efficacy. These include the generation of a
high molecular weight form of the chelator coupled to hydroxyethyl starch, lipophilic
DFO analogs, and libraries of structural DFO analogs (Kalinowski and Richardson
2005). Unfortunately, the evolution of DFO analogs has not resulted in chelators with
advantages over the original siderophore. Hence, other orally active alternatives have
been sought in the quest to develop effective and specific iron chelators.
Deferiprone
Deferiprone is an orally active hydroxypyridineone (Figure 4) first used in humans
in 1987. An advantage of this compound is that the iron(III) chelate of deferiprone
carries no net charge and therefore can penetrate membranes easily, allowing removal
of potentially toxic iron from tissues (Neufeld 2006). Deferiprone is available in Europe
and some other countries but not the United States (Kontoghiorghes et al. 2004). The
reasons for this difference in availability between countries is not entirely understood but
may be due to conflicting clinical trials related to the safety and iron clearing efficiency
of this ligand (Richardson, 2001).
As deferiprone is bidentate, three molecules are necessary to occupy the
coordination sites of iron. In biological systems, deferiprone appears to exhibit
incomplete coordination of iron which would enable access of reductants to the iron
core and may potentially lead to ROS production (Kalinowski and Richardson 2005).
Such findings could question the safety of deferiprone, and to overcome this problem
combination therapy with DFO has been assessed. Deferiprone often causes
gastrointestinal symptoms and idiosyncratic side effects including erosive arthritis
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(common in patients in South Asian countries, 5%-20% of patients), neutropenia (up to
5% of patients), and severe agranulocytosis (up to 0.5% of patients) (Neufeld 2006).
Thus, close monitoring is required.
To maintain a negative iron balance in overload patients, deferiprone must be
administered at a high daily dosage (75 mg/kg/d in 3 divided doses, up to 100 mg/kg)
(Balfour and Foster, 1999). The limited efficiency of deferiprone is due mainly to
extensive phase II drug metabolism in the liver where the hydroxyl group, essential for
chelation and iron clearance, undergoes glucuronidation (Liu and Hider 2002). The
metabolic inactivation of deferiprone has sparked research into the synthesis of other
hydroxypyridinones that do not undergo this form of modification in vivo.
Deferasirox
Deferasirox (ICL670, Exjade) belongs to a new class of oral tridentate chelators
N-substituted bis-hydroxyphenyltriazoles (Figure 4), that uses a triazolyl nitrogen and
two phenolic oxygens as donor groups. This ligand represents one of > 700 compounds
designed through computer modeling intended for the treatment of transfusional iron
overload (Nick et al. 2003). Deferasirox is selective for iron (as Fe3+) and binds iron with
high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper,
there are variable decreases in the serum concentration of these trace metals after the
administration of deferasirox. The clinical significance of these decreases is uncertain.
Deferasirox is orally active with 70% bioavailability and is marketed in the form of tablets
for oral suspension (Exjade®). It is highly (~99%) protein bound almost exclusively to
serum albumin and is mainly metabolized in the liver by glucuronidation. With a plasma
half-life of 8 to 16 hours, once-daily dosing permits circulating drug at all times to
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scavenge NTBI (Cappellini and Pattoneri 2009). Deferasirox-iron complexes undergo
enterohepatic recycling and are mainly excreted in the feces (84% fecal, 8% renal).
Females have a moderately lower apparent clearance (by 17.5%) for deferasirox
compared to males.
In addition to its ability to remove NTBI, a recent study has shown that
deferasirox can also cross the plasma membrane and enter the cell using unknown
carriers (Glickstein, El et al. 2005; Glickstein, El et al. 2006). Clinical studies have
demonstrated that after one year , deferasirox produced significant reduction in liver iron
concentration (Cappellini 2008). In animal models, deferasirox has been shown to be 5
times more potent than deferoxamine and 10 times more potent than deferiprone
(Choudhry and Naithani 2007).
Deferasirox is indicated for the treatment of chronic iron overload due to blood
transfusions (transfusional hemosiderosis) in patients 2 years of age and older. The
recommended initial daily dose of deferasirox is 20 mg/kg body weight. Doses of
deferasirox should not exceed 30 mg/kg per day since there is limited experience with
doses above this level. The decision to remove accumulated iron should be
individualized based on anticipated clinical benefit and risks of deferasirox therapy. In
patients who are in need of iron chelation therapy, it is recommended that therapy with
deferasirox be started when a patient has evidence of chronic iron overload, such as the
transfusion of approximately 100 mL/kg of packed red blood cells (approximately 20
units for a 40-kg patient) and a serum ferritin consistently >1000 µg/L.
The most frequently occurring adverse events in the therapeutic studies of
deferasirox were abdominal pain, nausea, vomiting, diarrhea, and skin rashes. Some
deferasirox-treated patients also experienced dose-dependent increases in serum
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creatinine, though most of the creatinine elevations remained within the normal range
(Cappellini 2005). Serum creatinine should be assessed in duplicate before initiating
therapy to establish a reliable pretreatment baseline and monitored monthly thereafter.
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Table 2. Comparison of the main available iron chelators to an ideal chelating
drug. (modified from Neufeld, 2006)

Route of

Ideal

Deferoxamine

Deferiprone

Deferasirox

Chelator

1970

1987

2005

Oral

S/C, IV

Oral

Oral

Long

Short (minutes);

Moderate

Long (8-6 hr);

enough to

requires constant

(<2 hr); required

remains in

prevent

delivery

t.i.d dosing

plasma 24 hr

High

Idiosyncratic side

High

administration

Plasma t1/2

NTBI
Therapeutic index

High

effects

Chelating efficacy/

High

High

Low

Moderate

Uncharged

Charged

Uncharged

Uncharged

None

Auditory and retinal

Agranulocytosis,

Abdominal

toxicity, effects on

neutropenia,

discomfort

bone and growth,

abdominal

rash, mild

lung toxicity, local

discomfort,

diarrhea

skin reactions

erosive arthritis

Lower than

High in clinical and

Insufficient

deferiprone and

in vitro studies

clinical data

charge

Side effects

High
Ability to chelate
intracellular

deferasirox

Promising
laboratory

cardiac & other

studies

tissue iron
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Figure 4. Chemical structure of the iron chelating agents in clinical use and their
corresponding iron binding ratio.

2.7 ANIMAL MODELS OF IRON OVERLOAD
Past efforts to study iron overload and its associated toxicity have been
hampered by the lack of a suitable experimental model of human iron overload; most
animal species have a far greater capacity to excrete iron than humans. Recently, the
Mongolian gerbil (Meriones unguiculatus) was developed as a model of iron overload
using weekly subcutaneous injections of iron dextran (Carthew, Dorman et al. 1993).
Studies using the gerbil model have reported that cardiac and hepatic iron content was
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increased to amounts within the range reported in patients with iron overload (Kuryshev,
Brittenham et al. 1999). In addition, the gerbil model tends to reproduce critical features
of the cardiomyopathy found in human iron overload as the gerbil seems unable to
excrete iron as effectively as other rodents. In one study, gerbils treated with repeated
injections of iron dextran over a period of months developed a cardiomyopathy that
resembles the cardiomyopathy that develops over a period of years in patients with
chronic iron overload (Kuryshev, Brittenham et al. 1999). Similarly, the accumulation of
iron in the gerbil heart has been associated with myocyte degeneration and intracellular
calcification, whereas in the hearts of mice treated identically with iron-dextran that had
accumulated comparable cardiac iron levels, similar evidence of myocyte damage was
absent (Yang, Dong et al. 2002). These results suggest that the gerbil model would be
useful in studying the progression of end organ damage associated with iron-overload.
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CHAPTER III
MATERIALS AND METHODS

This chapter outlines the procedures used for data collection and analysis in the
present study. The adult male Mongolian gerbil (Meriones unguiculatus) model of iron
overload was used. Iron overload was achieved by multiple intraperitoneal injections of
iron-dextran. Deferasirox treatment was administered orally at different time points after
the

completion

of

iron

loading.

Electrocardiographic

and

echocardiographic

measurements were conducted at baseline (before iron loading) and every three
months thereafter. After the completion of deferasirox treatment, gerbils were sacrificed
and heart, aorta, liver, kidney and pancreas were excised. Examination for changes in
tissue iron concentration, expression of ferritin, and cardiac morphology followed.

3.1 Animal selection and care
All experiments were conducted using male Mongolian gerbils. Adult male
Mongolian gerbils (Meriones unguiculatus) were obtained from Charles River
Laboratories and housed four per cage in an AALAC approved vivarium. Housing
conditions consisted of a 12h: 12h dark-light cycle with temperature maintained at 22 ±
2° C. Animals were provided food and water ad libitum.

Gerbils were allowed to

acclimate to the housing facilities for at least two weeks before experimentation began.
During this time, the animals were carefully observed. None of the animals exhibited
signs of failure to thrive, such as precipitous weight loss, disinterest in the environment,
or unexpected gait alterations. Animal care and procedures were conducted in
accordance with the Institutional Animal Care and Use Committee of Marshall University
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using the criteria outlined by the American Association of Laboratory Animal Care
(AALAC) as proclaimed in the Animal Welfare Act (PL89-544, PL91-979, and PL94279).

3.2 Iron loading and chelation
Gerbils were divided into Control (Ctrl), Iron overload (IO), and iron overload
followed by deferasirox treatment (IO+DFR). Iron treated animals received 15
subcutaneous injections of iron dextran (Sigma Chemical, St. Louis, Mo) at a dose of
100 mg/kg every 5 days for 10 weeks. Deferasirox was administered for one, three, or
nine months post iron loading. For each treatment group, an age-matched Ctrl and IO
group was maintained for comparison (Table 3).
To avoid the stress of chronic, repeated gavage feeding, deferasirox was
homogenously mixed in plain peanut butter (vehicle) for oral feeding via a 1-mL syringe.
Deferasirox powder was carefully blended or mixed with creamy, low-fat peanut butter
and the mixture placed into conical bakery squeeze applicators and delivered into 15mL plastic syringes which have had tips cut off. The mixture was then delivered into 1mL syringes with tips removed from which small volumes of the mixture containing the
desired quantity of drug was carefully introduced into the animal mouths and eaten. We
have found that animals acquire a taste for peanut butter after a few days of feeding
and thereafter eagerly consume the peanut butter. Therefore, the animals were
adjusted to peanut butter prior to administration of deferasirox-peanut butter mixtures.
This method of administration is equivalent to giving the drug with food or in
formulations of drug with filler material.
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Deferasirox treatment was started 1-week after the last iron dextran injection and
was given at a single daily dosage of 100 mg/kg. This dosage is based on a previously
determined dose-response curve of deferasirox in iron overloaded gerbils and
represents 67% of human values when normalized for body surface area (Wood, OttoDuessel et al. 2006). Oral chelator administration gave the animals approximately 0.15
mL of peanut butter per day. Control and iron overload groups received plain peanut
butter (vehicle) and were housed, fed, and maintained under identical conditions.

Table 3. Deposition of gerbils in the experimental groups
Interval
Baseline
1 months

3 months

9 months

Groups
n = 10/ group
Ctrl
IO
Ctrl
IO
IO+ DFR
Ctrl
IO
IO+ DFR
Ctrl
IO
IO+ DFR

Treatment
10 wk Saline
10 wk iron
10 wk Saline + 1 mo vehicle
10 wk iron + 1 mo vehicle
10 wk iron + 1 mo DFR
10 wk Saline + 3 mo vehicle
10 wk iron + 3 mo vehicle
10 wk iron + 3 mo DFR
10 wk Saline + 9 mo vehicle
10 wk iron + 9 mo vehicle
10 wk iron + 9 mo DFR

3.3 Electrocardiographic procedures
Gerbils were anesthetized with a ketamine (100 mg/ml)/xylazine (20 mg/ml)
mixture. EKG recording was performed using standard limb lead system (Biopac)®. To
emulate lead II, we utilized subcutaneously placed electrodes located in the line with the
long access of the heart. One electrode (anode) is placed in the upper right quadrant of
the chest and the other (cathode) in the lower left abdominal wall, just cranial to the
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groin area. Lead I configuration was performed by placing the cathode and the anode in
the upper right, and left quadrants of the chest, respectively. Lead III configuration was
performed by placing the cathode in the upper left quadrant of the chest, while the
anode was placed in the lower left abdominal wall.

3.4 Transthoracic echocardiography
Echocardiography is a noninvasive ultrasound procedure in which harmless,
high-frequency sound waves (frequency >20,000 cycles/sec) are emitted from a
piezoelectric crystal or transducer, beamed in particular directions, and reflected back
(echo) by small structures in the mm and sub-mm range. These waves are beamed
toward and penetrate the heart and are reflected back to the transducer as a series of
echoes, which are amplified and displayed on a cathode ray tube. It is used to evaluate
the position, size, and movement of cardiac valves, heart wall structure and function,
and directional flow of blood within cardiac chambers (Walker, Epling et al. 2007).
Animals were anesthetized with ip injections of a 2:1 mixture of ketamine HCl (100
mg/ml) and xylazine (20 mg/ml). Echocardiographic recordings were performed at the
Cabell Huntington Hospital, Huntington, WV. Gerbils were shaved in the chest area for
adequate sonic transference, an ultrasonic transmission gel was applied to the chest
area, and the animals were positioned on their left sides or backs. Two-dimensional
echocardiographic measurements, two-dimensional guided M-mode, Doppler M-mode,
and other recordings from parasternal long- (PLAX) and short-axis (PSAX) views were
obtained using a Phillips 5500 ECHO system with a 12 MHz transducer. Twodimensional measurements were used to image cardiac structures in the parasternal
long- and short-axis views. The echocardiographic views were then used to position the
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M-mode echocardiographic line. In the long-axis procedures, the probe was oriented
toward the base of the heart projecting toward the apex (x-axis) with depth along the yaxis, thus allowing pulse wave Doppler evaluation of valvular blood flow velocities. In
the short-axis procedures, the probe was oriented toward the left ventricle and across
the heart for evaluation of wall structure, which was utilized in the calculation of ejection
fraction and fractional shortening during systole. M-mode displays were analyzed by a
digital echocardiographic analysis system. Six measurements were selected for each
assessment of cardiac structure and function. The structural parameters included
diastolic (LVSd) and systolic (LVSs) left ventricular septal thickness, diastolic (LVIDd)
and systolic (LVIDs) left ventricular internal dimension, diastolic (LVPWd) and systolic
(LVPWs) left ventricular posterior wall thickness, and right ventricular diastolic internal
dimension (RV). Functional measurements included left ventricular ejection fraction
(EF), left ventricular fractional shortening during systole (FS), maximal aortic (AVmax),
pulmonary (PVmax), mitral (MVmax), and tricuspid (TVmax) valvular blood flow velocity.
Left ventricular ejection fraction (EF), and fractional shortening (FS) were used to
evaluate systolic function.

3.5 Tissue collection
Prior to sacrifice, gerbils were anesthetized with a ketamine-xylazine (4:1)
cocktail (50 mg/kg i.p.) and supplemented as necessary to achieve loss of reflexive
response. Loss of toe pinch and eye blink reflexes was assessed prior to the initiation of
any experimental manipulations. Every effort was made to minimize stress and
discomfort to the animals.
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After midline laparotomy, heart, liver, pancreas and aorta were removed and placed in
Krebs-Ringer bicarbonate buffer (KRB) containing: 118 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM NaHCO3, and 10 mM α-D-glucose
(pH 7.4) equilibrated with 5% CO2/ 95% O2 and maintained at 37°C. Isolated tissues
were quickly cleaned of connective tissue, weighed, and immediately snap frozen in
liquid nitrogen.

3.6 Tissue iron assessment
After sacrifice, portions of the heart, liver, kidney, pancreas, and aorta were
isolated, weighed, and sent for quantitative iron (total, heme plus non-heme, tissue iron)
determination (University of Tampa, Tampa, FL) by inductively coupled plasma-atomic
emission spectrometry (ICP-AES) (Walker, Epling et al. 2007). Briefly, digestions were
performed using commercially available trace metal grade HNO3 (ThermoFisher
Scientific). Dilutions were made with 2% (vol.) HNO3 (trace metal grade) prepared with
deionized water. All digestion tubes, volumetric pipettes, and volumetric glassware were
soaked for 24 hours in 2% (vol.) HNO3 (trace metal grade), rinsed four times with
deionized water, and air dried prior to use. Approximately 300 mg (wet weight) of
sample was weighed into a glass digestion tube and 6.0 ml of concentrated trace metal
grade HNO3 added. A 1000 mg/L Yttrium solution in 2% HNO3 (Perkin Elmer), used as
an internal standard (final concentration 1.67 mg/L), was added to each tube. Samples
were heated at 37oC for 1 hour and then at 110oC for 2 hours. After digestion, 5.0 ml of
the clear solution was transferred to a 50 ml volumetric flask and brought to volume with
2% (vol) HNO3 (trace metal grade). Solutions were filtered through a 0.22 μm syringe
driven filter unit (Millipore) and analyzed by ICP-AES. A 1.67 mg/L iron solution was
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used as a control for the digestion procedure. Analyses were performed on a Perkin
Elmer ICP-AES (Optima 2100 DV) using a 0 to 1 mg/L, 0 to 10 mg/L, or 0 to 100 mg/L
(for iron only) standard curve, depending upon iron concentration. Calibration and
control solutions for the 0 to 1 mg/L and 0 to 10 mg/L standard curves were prepared
from a multi-element standard (ICP Multi-element Solution 2, Spex Chemicals, 10
mg/L). Calibration and control solutions for the 0 to 100 mg/L standard curve were
prepared from a 1000 mg/L iron standard solution (Perkin Elmer). All calibrators and
controls contained an internal Yttrium standard. The measurements for iron (238.204
nm) were conducted in the axial mode. Sample concentrations were determined from
standard curves generated by linear regression analysis. The minimal detectable
concentration for each metal was determined using the mean plus the three-fold
standard deviation obtained from 10 blank digestions.

3.7 Histological analysis
Whole hearts (breadloaf sectioned) and representative sections of liver,
pancreas, and aorta were fixed in 10% buffered formalin solution, and processed into
paraffin blocks by routine procedures. Samples were then sectioned (8 μm) with a
cryostat and sections were mounted on poly-lysine (Sigma, St. Louis, MO) coated
slides. Sections were stained with Prussian blue iron stain. Slides were evaluated by
light microscopy and images were taken at 200X, or 400X. This data was collected and
reviewed in a blinded fashion.
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3.8 SDS-PAGE and immunoblotting
Tissue was pulverized in liquid nitrogen using a mortar and pestle until a fine
powder was obtained. After washing with ice cold PBS, samples were lysed on ice for
15 minutes in T-PER (2 mL/1 g tissue weight) and centrifuged for 10 minutes at 12000 x
g. The supernatant was collected and the protein concentrations of homogenates were
determined in triplicate via the Bradford method (Pierce) using bovine serum albumin as
a standard. Samples were solubilized at a concentration of 3 mg/ml in SDS-loading
buffer and boiled for 5 minutes. Sixty µg of protein from each sample was separated on
10% SDS-PAGE gels and then transferred onto Hybond nitrocellulose membranes
using standard conditions. To verify transfer of proteins and equal loading of lanes, the
membranes were stained with Ponceau S. Membranes were blocked in buffer (5%
nonfat dry milk in tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hour at room
temperature, washed (TBST, 3 X 5 minutes), and incubated in primary antibody (1:1000
dilution) in TBST with 5% milk overnight at 4ºC. After washing (TBST, 3 X 5 minutes),
membranes were incubated in horseradish peroxidase HRP-linked anti-biotin and the
appropriate secondary antibody (1:1000 dilution) in TBST with 5% milk for 1 hour at
room temperature, then rewashed (TBST, 3 X 5 minutes). Proteins were visualized by
ECL and quantified by densitometry.

Exposure times were adjusted to keep the

integrated optical densities (IOD) of the film within a linear and nonsaturated range.
Specificity of the bands was assessed by comparison of molecular weight markers and
positive controls. To allow direct comparisons to be made between the expression
levels of different signaling molecules and the amount of protein present, immunoblots
were stripped with Restore western blot stripping buffer and reprobed as detailed by the
manufacturer. After verifying the absence of residual HRP activity, membranes were
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washed and reprobed for other proteins. All membranes were probed for GAPDH for
analysis and loading control.

3.9 Oxidative fluorescent microscopy
Cardiac or hepatic specimens were serially sectioned (8 μm) using an IEC
Minotome cryostat and collected on poly-lysine coated slides. Hydroethidine (HE), an
oxidative fluorescent dye, was used to visualize superoxide (O2•–) production in situ
(Miller, Gutterman et al. 1998; Lund, Faraci et al. 2000). Hydroethidine freely permeates
the cells and, in the presence of O2•–, is oxidized to ethidium bromide, which is trapped
by intercalating with the DNA (Rothe, Emmendorffer et al. 1991). Because ethidium
bromide is impermeable to cell membranes, extracellular O2•– would not be expected to
contribute significantly to the observed cellular fluorescence. Neither hydroxyl radical,
nitric oxide radical, peroxynitrite, hydrogen peroxide, hypochlorite, nor singlet oxygen
significantly oxidize hydroethidine; as such, an increase in ethidium bromide
fluorescence is thought to indicate O2•– generation specifically within the fluorescing
cell. Heart sections were stained with hydroethidine and visualized under fluorescence
as described previously (Rice, Preston et al. 2006). The intensity of fluorescent ethidium
bromide-stained nuclei was calculated by digitizing images and then determining the
average pixel intensity of six randomly positioned regions (1000 μm2) per cross section.
Morphometric evaluation was performed with the use of a computerized imaging
analysis system (Olympus MicroSuite™ Basic).
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3.10 Oxidized Protein Analysis
Cardiac and hepatic protein isolation was conducted as described above. To
identify carbonyl groups that are introduced into the amino acid side chain after
oxidative deamination of proteins, oxyblot analysis was performed. The level of protein
oxidation was determined by an Oxidized Protein Detection Kit (Oxyblot, Chemicon
Cat#

S7150-Kit).

Oxyblot

kit

derivatizes

carbonyl

groups

to

a

2,

4-

dinitrophenylhydrazone (DNP) moiety. The DNP moiety can then be detected using
anti-DNP antibodies and is a method to assay for one form of oxidative damage to a
protein. The proteins are derivatized as per the protocol given in the kit. These proteins
are separated on 10% SDS-PAGE gels and transferred onto nitrocellulose membrane.
After the transfer, membranes were blocked with 2.5% BSA in Tris Buffered Saline
(TBS) with 0.2% Tween-20 for 1 hour at room temperature. The nitrocellulose
membrane was exposed to a primary rabbit anti-DNPH protein antibody from Chemicon
Oxyblot (1:200 working dilution) for 1 hour, and then to a secondary antibody (Goat
Anti-Rabbit IgG (HRP-conjugated) diluted in the blocking solution 1:500 for 1 hour at
room temperature. Membranes were washed after every step in washing buffer (TBS
with 0.2% Tween-20). Protein bands were visualized with ECL (Amersham
Biosciences). Band signal intensity was quantified by densitometry using a flatbed
scanner (Epson Pefection 3200 PHOTO) and Imaging software (AlphaEaseFC).

3.11 In situ cell death detection (TUNEL)
Liver samples were cut into serial 8μm sections using an IEC Minotome Cryostat.
After fixing with 4% paraformaldehyde, sections were washed with phosphate-buffered
saline (PBS, pH7.4), and then permeabilized with 0.1% sodium citrate and 0.1% Triton
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X-100. DNA fragmentation was determined by TdT-mediated dUTP nick end labeling
(TUNEL) as suggested by the manufacturer’s recommendations. Cross-sections from
each liver were treated with DNase I to induce DNA fragmentation as a positive control.
Three randomly selected regions from each cross section were visualized by
epifluorescence using an Olympus fluorescence microscope (Melville, NY) fitted with a
40X objective. Images were recorded digitally using a CCD camera (Olympus, Melville,
NY), and the samples were analyzed by counting positively stained nuclei with DAPI
nuclear staining for contrast.

3.12 Statistical analysis
Results are presented as mean ± SEM. Data were analyzed by using SigmaStat
3.0 computer software. One-way (or two-way) analysis of variance (ANOVA) was used
for overall comparisons where appropriate with the Student-Newman-Keuls post hoc
test used to determine statistical significance. The level of significance accepted a priori
was P ≤ 0.05.

3.13 Materials
Deferasirox powder used in the study was provided by Novartis Pharmaceuticals
(East Hanover, NJ). Primary antibodies against P-ERK1/2 MAPK (Thr202, Tyr204) (cat
#9106), p-p38 MAPK (Thr180, Tyr182) (cat#9216), p-JNK (Thr183, Tyr185) (cat #9251),
ERK1/2 MAPK (cat #9102), p38 MAPK (cat #9218), JNK (cat #9252), caspase-3
(#9662), anti-biotin as well as anti- mouse and -rabbit secondary antibodies, and NIH
3T3 cell lysates were obtained from Cell Signaling Technology (Beverly, MA). Anti-Bax
(N-20) (sc-492), Bcl-2(C-2) (sc-7382), and Bad (H-168) (sc-7869), ferritin heavy chain
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(H-53) (cat #25617) and anti-goat secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). The TUNEL assay kit was purchased from Roche
Diagnostics Corporation (Indianapolis, IN). Precast 10% and 15% SDS-PAGE gels
were procured from Cambrex Biosciences (Baltimore, MD) while the enhanced
chemiluminescence (ECL) Western blot detection reagents, Hyperfilm, and Hybond
nitrocellulose membranes came from Amersham Biosciences (Piscataway, NJ).
Restore western blot stripping buffer and T-PER tissue lysis buffer were obtained from
Pierce (Rockford, IL).

Dual Color molecular weight markers were from BioRad

(Hercules, CA). All other chemicals were purchased from Sigma (St. Louis, MO).
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CHAPTER IV
RESULTS
The results chapter will be subdivided into three articles.

Each article will deal

specifically with a specific aim of the dissertation project.
Note: The method section has been omitted from these articles to avoid redundancy.
Please refer to Chapter III for detailed materials and methods.

Article #1: Corresponds to Specific Aim #1
To determine if deferasirox is able to reduce cardiac iron content, iron-induced
ferritin upregulation, and iron-related increases in indices of oxidative stress such
as superoxide overproduction, protein oxidation, and the phosphorylation of the
extracellular regulated kinase 1/2 (ERK1/2)-, p38-, and c-Jun N-terminal kinase
(JNK)-mitogen activated protein kinases (MAPKs).
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Abstract
Iron-induced cardiovascular disease is the leading cause of death in ironoverloaded patients. Deferasirox is a novel, once daily oral iron chelator that was
recently approved for the treatment of transfusional iron overload. Here, we investigate
whether deferasirox is capable of removing cardiac iron and improving iron-induced
pathogenesis of the heart using the iron overload gerbil model. Animals were randomly
divided into three groups: control, iron overload, and iron overload followed by
deferasirox treatment. Iron-dextran was given 100 mg/kg per 5 days i.p for 10 weeks.
Deferasirox treatment was started post iron loading and was given at 100 mg/kg/day p.o
for 1- or 3- months. Cardiac iron concentration was determined by inductively coupled
plasma atomic emission spectroscopy. Compared with the untreated group, deferasirox
treatment for 1- and 3- months decreased cardiac iron concentration 17.1% (P = 0.159)
and 23.5% (P < 0.05), respectively. These treatment-associated reductions in cardiac
iron were paralleled by decreases in tissue ferritin expression of 20% and 38% at 1 and
3 months, respectively (P < 0.05). Using oxyblot analysis and hydroethidine
fluorescence, we showed that deferasirox significantly reduces cardiac protein oxidation
and superoxide abundance by 47.1% and 36%, respectively (P < 0.05). Iron-induced
increase in oxidative stress was also associated with increased phosphorylation of
ERK1/2-, p38-, and JNK-mitogen-activated protein kinases (MAPKs). Interestingly,
deferasirox treatment significantly diminished the phosphorylation of all three MAPK
subfamilies. These results suggest that deferasirox may confer a cardioprotective effect
against iron induced injury.
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Introduction
Excessive body iron or iron overload in thalassemia and other conditions is a
serious health issue the world over (Hershko 2007). Increased cardiac iron deposition is
the leading cause of morbidity and mortality in transfusion-dependent patients as these
conditions are oftentimes associated with diastolic dysfunction, arrhythmias, and dilated
cardiomyopathy (Walker, Epling et al. 2007). The mechanism(s) by which increased iron
affects cellular function are not well understood; however, increases in reactive oxygen
species (ROS) have been posited to be involved as current data has suggested a
strong link between elevations in cardiac ROS levels and cardiac dysfunction (Oudit,
Trivieri et al. 2004).
In the past, iron overload was treated with deferoxamine and deferiprone,
although effective, treatment compliance was frequently compromised as the
administration of these compounds is often burdensome or associated with serious side
effects (Hershko, Link et al. 2005; Neufeld 2006). Deferasirox is a recently approved,
orally administered tridentate iron chelator that is administered on a once-daily regimen
(Vichinsky 2008). Initial findings regarding the use of deferasirox have suggested that
this chelator is very effective in removing liver iron, while other data have suggested that
deferasirox may be effective in diminishing cardiac iron (Rachmilewitz, Weizer-Stern et
al. 2005; Pennell, Porter et al. 2008; Pennell, Sutcharitchan et al. 2008). The primary
objective of this investigation was to determine if chronic administration of deferasirox is
capable of removing excess iron from the heart in the gerbil model of iron overload. We
hypothesized that deferasirox would reduce cardiac iron content and that this reduction,
if present, would be associated with diminished cardiac ROS.
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Results
Characterization of animals
Total body and liver weights were obtained and compared. All animals tolerated
the iron loading and chelation without any apparent ill effects. The body weights of iron
overloaded gerbils were similar to controls, indicating that the injection of iron dextran
did not result in debilitation or weight loss. Heart/ body weight ratio was ~20% higher in
the IO group compared to the Ctrl group (P < 0.05) (Table 4). No significant difference
was observed after one or three months of follow up or with deferasirox treatment.

Table 4. Deposition of gerbils in the experimental groups and heart/body weights.
Interval

Groups

Treatment

Heart/ body wt (%)

Ctrl

10wk saline

0.41 ± 0.04

IO

10wk iron

0.49 ± 0.02*

Ctrl

10 wk saline + 1mo vehicle

0.42 ± 0.01

IO

10 wk iron + 1 mo vehicle

0.43 ± 0.01

IO+ DFR

10 wk iron + 1 mo DFR

0.42 ± 0.01

Ctrl

10 wk saline + 3 mo vehicle

0.38 ± 0.01

IO

10 wk iron + 3 mo vehicle

0.39 ± 0.01

IO+ DFR

10 wk iron + 3 mo DFR

0.38 ± 0.01

n = 10/ group

Baseline

1 months

3 months

An asterisk (*) indicates significant difference from age matched control

Cardiac iron levels
Cardiac iron levels were measured using inductively coupled plasma atomic
emission spectrometry (ICP-AES). Compared to hearts obtained from control animals,
iron overload increased cardiac iron level by 10.4 fold (P < 0.05). Cardiac iron levels
were 8.1- and 7.4-fold higher than that of the corresponding age-matched controls at
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one and three months of follow up, respectively (P < 0.05). Compared to the 3 month-IO
group, deferasirox treatment decreased cardiac iron levels by 23.5% (P < 0.05) (Figure
5). Prussian blue staining demonstrated elevated iron deposition in cardiac sections
from gerbils in the 3 month-IO group (Figure 6). Iron deposition exhibited a
nonhomogenous distribution with a higher deposition in the ventricle compared to atria.
In the left ventricular wall, iron accumulation was higher in the epicardium and
endocardium, and was the least in the myocardium. Within the myocardium, iron tended
to accumulate in the interstitium although deposition was clearly visible inside the
myocytes. Deferasirox treatment for three months produced a notable decrease of
stainable iron visible in all regions of the heart (Figure 6).

Figure 5. Average iron levels in mg/g tissue weight in cardiac tissue of gerbils in
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload
followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval. (*)
indicates significant difference from control, (†) indicates significant difference from iron
overload group (P < 0.05).
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Figure 6. Histological examination of left ventricular myocardium of Ctrl (A), IO
(B), and IO+DFR (C) gerbils followed for 3 months. Ferric iron was detected by
Prussian blue staining. No apparent iron deposition was observed in control gerbils. Iron
overload resulted in iron accumulation in endothelial cells in cardiac interstitium and to a
lesser extent in cardiac myocytes. Deferasirox treatment diminished iron deposition
from all regions of cardiac tissue. Bar represents 100 µm, Images were taken at 400X
original magnification.

Ferritin protein expression
Cardiac ferritin protein levels were analyzed by immunoblot using total protein
isolates from each of the experimental groups. Compared to control animals, ten weeks
of iron overload increased ferritin protein by 1.9 fold (P < 0.05) (Figure 7). After
completion of iron loading ferritin levels remained elevated and were 1.7 and 1.6 fold
higher than that of the corresponding age-matched control after one and three months
of follow up, respectively (P < 0.05). Deferasirox treatment significantly reduced cardiac
ferritin expression by 20% and 38% after one (1m-IO+DFR) and three months (3mIO+DFR) of treatment, respectively (P < 0.05).
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Figure 7. Effect of iron overload and iron chelation on ferritin heavy chain (FerH)
protein expression in cardiac tissue of gerbils in the experimental groups. (Upper
panel) Results were obtained from six experiments in each group and expressed as a
percentage of the corresponding age matched control value. (Lower panel)
Representative Western blot analysis. Ctrl: control, IO: Iron overload, IO+ DFR: Iron
overload followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval.
(*) indicates significant difference from control, (†) indicates significant difference from
iron overload group (P < 0.05).

Superoxide abundance
Because increased iron accumulation has been found to be associated with
increased oxidative stress, we examined cardiac tissue sections from Ctrl, IO, and
IO+DFR groups from 3 months interval for superoxide generation using HE
fluorescence. Compared to 3 months-Ctrl, a 101% increase in HE fluorescence was
observed in the 3 months-IO groups (P < 0.05). Three months of deferasirox treatment
(3mIO+DFR) resulted in 36% reduction in HE fluorescence (P < 0.05) (Figure 8). The
overall distribution of superoxide abundance appears to be similar in all regions of the
cardiac myocardium (Figure 8).
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Figure 8. Detection of cardiac superoxide by dihydroethidium in Ctrl, IO, and
IO+DFR groups. (Upper panel) The increase in superoxide involves all layers of
ventricular wall. Bar represents 100µm, images were taken at 400X original
magnification. (Lower panel) Quantification of cardiac superoxide as determined by
intensity of fluorescent ethidium bromide-stained nuclei from six animals in each group.
3m = 3 months interval. An asterisk (*) indicates significant difference from control
animals, (†) indicates significant difference from iron overload (P < 0.05).

Protein oxidation
To investigate whether iron overload modifies cardiac proteins, we next
examined protein isolates obtained from the hearts of Ctrl, IO, and IO+DFR for three
months for the presence of carbonylated protein using OxyBlot™ detection kit. Protein
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carbonylation was increased by 114% in the 3 month-IO group compared to that of
3months-Ctrl (P < 0.05). These levels were reduced by 47% after three months of
deferasirox treatment (3mIO+DFR) (P < 0.05) (Figure 9).

Figure 9. Effect of iron overload or deferasirox treatment on cardiac protein
carbonylation. (Left) Representative oxyblots of cardiac protein isolates from ctrl, IO,
and IO+DFR from 3 months interval. (Right) Quantification of oxidatively modified
proteins in the corresponding groups. 3m = 3 months interval. An asterisk (*) indicates
significant difference from control animals, (†) indicates significant difference from iron
overloaded animals (P < 0.05).
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Determination of ERK1/2-, p38-, and JNK-MAPK phosphorylation
The MAPK pathway has been identified as an important signaling cascade
involved in the control of cell growth, differentiation, and adaptation whose activity is
thought to be regulated, at least in part by cellular ROS levels (Martindale and Holbrook
2002). No significant difference in ERK1/2, P38, or JNK-MAPK protein expression was
observed between groups. ERK1/2-MAPK phosphorylation was 67%, 50%, and 58%
higher in the IO, 1 month-IO, 3 months-IO groups compared to the corresponding age
matched control, respectively (P < 0.05). Deferasirox treatment for one or three months
significantly reduced ERK1/2 phosphorylation by 13% and 32%, respectively (P < 0.05)
(Figure 10A). p38-MAPK phosphorylation was 164%, 218%, and 134% higher in the IO,
1 month-IO, 3 month-IO groups compared to the corresponding age-matched control,
respectively. Similar to our findings for ERK1/2, the phosphorylation of p38-MAPK was
decreased 33% and 46% after one and three months of deferasirox treatment,
respectively (Figure 10B). Likewise, JNK-MAPK phosphorylation, was 52%, 50%, and
98% higher in the IO, 1 month-IO, 3 month-IO groups compared to the corresponding
age-matched control, respectively (P < 0.05) (Figure 10C). Deferasirox treatment
significantly reduced the phosphorylation of JNK-MAPK by 27%, and 47% after one and
three months of chelation, respectively (P < 0.05) (Figure 10C).
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Figure 10. Effect of iron overload or deferasirox treatment on the expression of
total and phosphorylated ERK1/2-, P38-, and JNK-MAPKs. (Left) Representative
western blot demonstrating the expression of total and phosphorylated ERK1/2-, P38-,
and JNK-MAPK in the hearts in the experimental groups. (Right) Quantification of
protein expression of p-ERK1/2- (A), p-P38- (B), p-JNK-MAPKs (C) in the
corresponding groups. Results are expressed as a percentage of the corresponding age
matched control value. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed
by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval. (*) significantly
different from control group; (†) significantly different from iron overload group (P < 0
.05).

Discussion
The accumulation of cardiac iron is a complication of iron overload in transfusiondependent patients that if allowed to proceed unchecked can lead to cardiac
arrhythmias and heart failure (Wood, Otto-Duessel et al. 2006). This study
demonstrated that oral deferasirox administration significantly reduces cardiac iron
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levels in the iron-overloaded Mongolian gerbil. In addition, our data demonstrates that
these deferasirox-induced decreases in cardiac iron were associated with diminished
indices of cardiac reactive oxygen species (ROS), and decreased activation of MAPK
signaling.
Deferasirox decreases cardiac iron and ferritin levels in the iron overloaded gerbil
The similarities of iron accumulation, distribution, and associated pathology in
gerbil and human hearts have suggested that the Mongolian gerbil iron-overload model
may mimic many of the events seen in the iron-overloaded human (Kaiser, Davis et al.
2003). Our findings demonstrated that iron loading for ten weeks resulted in a 10.4 fold
increase in cardiac iron concentration (Figure 5). Although decreasing slightly, tissue
iron concentration in the iron overloaded animals remained elevated one- (8.1 fold) and
three- (7.4 fold) months following discontinuation of iron administration. Three months of
oral deferasirox treatment significantly reduced cardiac iron concentration by 23.5%
compared to the corresponding untreated group (Figure 5). This decrease in tissue iron
levels with treatment was consistent with previous reports that have used a similar
duration of iron loading and deferasirox treatment (Wood, Otto-Duessel et al. 2006;
Otto-Duessel, Aguilar et al. 2007; Walker, Epling et al. 2007). For example, Wood and
colleagues (2006) have demonstrated that deferasirox treatment for 12 weeks reduced
cardiac iron content 20.5%. In an effort to expand upon these findings, we also
performed Prussian blue iron staining of cardiac tissue sections. As expected, and
similar to previous studies (Otto-Duessel, Aguilar et al. 2007; Otto-Duessel, Brewer et
al. 2008), we observed increases in cardiac iron deposition with iron overload and what
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appears to be a similar reduction in the amount of tissue iron following deferasirox
treatment (Figure 6).
To explore the effect of deferasirox on iron overload further, we also examined
the regulation of ferritin protein levels in the heart. Ferritin is the major iron-storage
protein at the cellular and organismal level. The ferritin protein is typically increased with
iron overload (Tran, Eubanks et al. 1997) as this molecule is thought to be responsible
for the sequestration of potentially harmful, reactive iron (de Valk and Marx 1999). Using
immunoblotting, we demonstrate that iron-overload was associated with a robust
induction of ferritin protein in the heart (Figure 7). As predicted from our ICP-AES data,
we further demonstrate that deferasirox treatment significantly decreased cardiac ferritin
levels (Figure 7). Taken together, these results are consistent with the notion that oral
deferasirox administration is capable of reducing cardiac iron.
Reduced cardiac iron levels are associated with decreases in tissue ROS
Excess "labile iron" is potentially detrimental to the cell because of its propensity
to participate in oxidation-reduction reactions that generate harmful free radicals (Deb,
Johnson et al. 2009). In addition, it is also thought that a chronic elevation in tissue iron
levels can lead to depletion of antioxidants which, if not restored, can by itself lead to
further ROS elevation and provide a mechanism for further dysfunction (Eaton and Qian
2002; Oudit, Trivieri et al. 2004). Whether exogenous antioxidant supplementation can
be used to prevent such changes remains to be determined. For example, previous
reports using selenium and vitamin E, but not taurine, failed to show improvement in
indices of oxidative stress in gerbil (Otto-Duessel, Aguilar et al. 2007). Although the
physiological effects of reduced superoxide levels following iron chelation were not
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investigated in the present study, it has been previously demonstrated that excess
superoxide can result in the production of iron-catalyzed hydroxyl radicals (Bartfay,
Dawood et al. 1999; de Valk and Marx 1999) and mitochondrial dysfunction (Afanas'ev
2005). Whether these events are occurring in the current study and if they are
diminished by iron chelation is not clear.
To explore other ROS-related effects of iron overload and iron chelation, we also
examined protein oxidation by determining the amount of protein carbonylation. Our
data demonstrate that iron-overload was associated with increased levels of protein
oxidation in the heart (Figure 9) and importantly, that deferasirox treatment is capable of
decreasing the amount of oxidized proteins in the iron overloaded gerbil heart. Although
the physiological effects of protein oxidation in the heart are not entirely elucidated,
recent work has suggested that protein oxidation can alter protein function and
conformation (Crowder and Cooke 1984; Hertelendi, Toth et al. 2008).
Reduced cardiac iron levels are associated with decreases in iron-associated MAPK
phosphorylation
Recent data has suggested that increased ROS levels can trigger the activation
of multiple signaling pathways including mitogen-activated protein kinases (MAPKs)
(Martindale and Holbrook 2002). In addition, several lines of evidence have indicated
that the MAPK proteins may be involved in cardiovascular remodeling and that the
phosphorylation (activation) of these proteins is associated with the development of
cardiac hypertrophy (Molkentin 2004; Wenzel, Muller et al. 2005). Here, we
demonstrate that iron overload was associated with increased MAPK phosphorylation
and that this effect was reversed following deferasirox treatment (Figure 10). These
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data are consistent with previous work of Dai and colleagues who demonstrated in
primary hepatocytes that increased intracellular iron was associated with increased
ERK1/2- and p38-MAPK phosphorylation (Dai, Huang et al. 2004). Whether the
observed changes in MAPK phosphorylation are directly related to changes in tissue
iron concentration, indices of tissue ROS or other factors is not known and cannot be
determined from the present study design. Nonetheless, it is interesting that tissue iron
levels appeared to affect each of the MAPK proteins differently. For example,
phosphorylated ERK1/2 levels appeared to be maximal directly after completion of the
iron loading while conversely, the phosphorylation of the p38- and JNK-MAPK proteins
was not maximal until one and three months of iron overload, respectively. Furthermore,
the magnitude of p38-MAPK phosphorylation appears to be greater than that seen for
either ERK1/2- or JNK-MAPK, possibly suggesting that p38-MAPK phosphorylation in
the heart may be more sensitive to increased iron (or stress) than either the ERK1/2 or
JNK proteins.
In summary, the present study demonstrates an important in vivo association
between iron chelation, oxidative stress, and MAPK phosphorylation. Whether the
observed changes may relate or contribute to complications seen in transfusional iron
overload is currently unclear. Further, the effect of alternative treatment regimens is not
clearly understood. Otte-Duessel et al. (2007) have suggested that twice-daily dosing of
deferasirox appears to improve cardiac iron elimination compared to that observed
using single daily dosing protocol. In addition, the administration of deferasirox in
combination with deferoxamine produced no additive effect on the cardiac iron levels
above that observed with deferasirox alone (Otto-Duessel, Aguilar et al. 2007). Whether
this effect is due to limitations in the gerbil model itself (Otto-Duessel, Aguilar et al.
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2007) or is applicable to other models remains to be determined. As such, clinical
implications have to be evaluated carefully. Better understanding of the how cardiac iron
levels may affect tissue ROS and function will no doubt be useful to improving clinical
guidelines for cardioprotection.
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Article #2: Corresponds to Specific Aim #2
To determine if deferasirox is able to reduce hepatic iron content, iron-induced
ferritin upregulation, and iron related increases in indices of oxidative stress and the
effect of these changes, if present, on the incidence of iron-related changes in cell
death and apoptotic signaling.
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Abstract
Iron overload is associated with an increased risk of developing liver
complications including fibrosis, cirrhosis, and hepatocellular carcinoma. Deferasirox is
a novel oral chelator with high iron-binding potency and selectivity. Here, we investigate
the ability of deferasirox to remove excessive hepatic iron and prevent or reverse iron
induced hepatic injury. Adult male Mongolian gerbils were randomly divided into three
groups: control, iron overload, and iron overload followed by deferasirox treatment. Iron
overload animals received iron dextran 100 mg/kg i.p /5 d for 10 wks while deferasirox
was given 100 mg/kg/d p.o for 1 or 3 months. Compared to the non-treated iron
overload group, deferasirox treatment reduced hepatic iron levels by 43.5% after three
months of treatment (P < 0.05). Histological analysis detected frequent iron deposition,
evidence of hepatic damage, and lipid accumulation in hepatic tissue of the iron
overloaded group. Iron deposition was significantly diminished with deferasirox
treatment and no evidence of lipid accumulation was observed. Immunoblotting
demonstrated that iron overload caused about a two fold increase in hepatic ferritin
expression (P < 0.05), which was reduced by 47.5% following three months of
deferasirox treatment (P < 0.05). In addition, deferasirox significantly reduced hepatic
protein oxidation and superoxide abundance. The percentage of TUNEL-positive nuclei
in the deferasirox treated livers was 41.0% lower than that of the iron overloaded group
(P < 0.05). Similarly, iron related increase in the expression of Bax/Bcl-2, Bad, and
caspase-3 were significantly lower following deferasirox treatment. These findings
suggest that deferasirox may confer protection against iron induced hepatic toxicity.
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Introduction
Iron overload is associated with liver, pancreatic, and cardiac dysfunction and is
potentially deadly if improperly managed (Gordeuk, Bacon et al. 1987). The incidence of
iron overload appears to be increasing, and it has been estimated that this disorder now
afflicts over 100 million worldwide (Kontoghiorghes 2006). Most often, iron overload is
seen in those with hereditary hemochromatosis and in individuals that must undergo
frequent blood transfusions (Gordeuk, Bacon et al. 1987). The etiology of iron overload
is thought to be governed by the magnitude of the body iron burden, the rate at which
the increase in body iron has occurred, and the distribution of the excess iron within the
body (Kushner, Porter et al. 2001). The management of iron overload may be achieved
by pharmacologic chelating agents such as deferoxamine, deferiprone, and Deferasirox
(Olivieri and Brittenham 1997). Deferoxamine (DesferalR) is presently the standard of
care for the first-line treatment of transfusional iron overload (Brittenham, Griffith et al.
1994). Although effective in removing iron, treatment compliance is oftentimes
compromised given that deferoxamine administration requires overnight subcutaneous
infusions, 5-7 nights/week (Hershko, Link et al. 2005; Neufeld 2006). In contrast to the
burden associated with deferoxamine treatment, deferasirox (ExjadeR, ICL670) is given
orally using a once-daily regimen. Although initial findings have been very promising,
information regarding the effect of deferasirox on hepatic iron handling is lacking.
It is thought that the toxic effect of iron is due, at least in part, to the generation of
reactive oxygen species (ROS) through the Fenton reaction where iron mediates the
oxidation of free radical intermediates such as superoxide anion (O2•–) or hydrogen
peroxide (H2O2) to highly toxic free radicals such as hydroxyl radical (HO•) (Storz and
Imlay 1999). Here, we investigate whether deferasirox is capable of removing excess
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iron from liver and the effect of iron removal, if present, on hepatic ROS. We
hypothesized that deferasirox treatment would reduce hepatic iron content and that this
decrease in iron would be associated with decreases in ROS that will, in turn, be
strongly associated with the reversal or reduction of iron-induced changes in hepatic
structure and function.

Results
Characterization of animals
Total body and liver weights were obtained and compared . All animals tolerated
the iron loading and chelation without any apparent ill effects. The body weights of iron
overloaded gerbils were similar to controls, indicating that the injection of iron dextran
did not result in debilitation or weight loss. Liver weights were increased 52% after 10
weeks of iron overload and remained elevated after one and three months follow up (P
< 0.05) (Table

5). Deferasirox treatment was effective in reducing iron-associated

increases in whole liver weight (Table 5).
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Table 5. Deposition of gerbils in the experimental groups and liver/body weights.
Interval

Groups

Treatment

Liver/ body wt (%)

Ctrl

10wk saline

3.10 ± 0.17

IO

10wk iron

4.72 ± 0.21*

Ctrl

10 wk saline + 1mo vehicle

3.71 ± 0.14

IO

10 wk iron + 1 mo vehicle

5.77 ± 0.21*

IO+ DFR

10 wk iron + 1 mo DFR

5.20 ± 0.17*+

Ctrl

10 wk saline + 3 mo vehicle

3.63 ± 0.08

IO

10 wk iron + 3 mo vehicle

5.47 ± 0.20*

IO+ DFR

10 wk iron + 3 mo DFR

4.51 ± 0.15*+

n = 10/ group

Baseline

1 months

3 months

An asterisk (*) or cross (+) indicates significant difference from age matched control or
iron overload groups, respectively.

Hepatic iron levels
Hepatic iron levels were elevated 90 fold compared to age matched controls after
iron overload injections (P < 0.05). Hepatic iron levels exhibited gradual reduction to
76.5 and 57.8 fold at one month and three months post overload, respectively (P <
0.05). Deferasirox treatment decreased hepatic iron level by 43.5% after three months
of treatment (P < 0.05) (Figure 11). These observations were consistent with hepatic
Prussian blue staining results in which iron overloaded hepatic tissue exhibited
frequently elevated iron deposits in all regions of the hepatic plate but especially
concentrated in the periportal region (Figure 12, C). Interestingly, deferasirox produced
striking hepatocyte clearing from all regions of hepatic plate (Figure 12, D).In addition,
we observed an increase in lipid accumulation as vacuoles in the hepatocytes of the
iron overloaded group (Figure 12, B). These vacuoles were not apparent in hepatic
tissue from either control or deferasirox treated groups.
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Figure 11. Average iron levels in mg/g tissue weight in hepatic tissue of gerbils in
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload
followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval. (*)
indicates significant difference from control, (†) indicates significant difference from iron
overload group (P < 0.05).
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Figure 12. Iron deposition in hepatic tissue of Ctrl (A), IO (B,C), and IO+DFR(D)
gerbils followed for 3 months. Ferric iron was detected by Prussian blue staining. (A)
demonstrates no apparent iron deposition in the liver of control gerbils (200X). (B)
depicts iron induced damage and lipid accumulation in hepatocytes as vacuoles (Arrow,
400X). (C) shows iron accumulation in all areas of hepatic plate, but especially
concentrated in the periportal region (200X). Large, intensely stained lobular masses
represent macrophages. (D) demonstrates decreased iron deposition in all areas of
deferasirox treated hepatic tissue (200X). Iron accumulation manifests as blue
background staining at this magnification but is discernible as discrete deposits “dots” at
higher power
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Ferritin protein expression
We investigated whether the elevation in hepatic iron levels with iron overload is
associated with an increase in hepatic ferritin protein expression using Western blot
analysis. As expected, ferritin protein expression was 2.4 fold higher after ten weeks of
iron overload. Ferritin levels decreased slowly over time, and it was 2.2 fold, and 2.1
fold at one and three months follow up. Interestingly, one and three months of
deferasirox treatment resulted in 23%, and 47.5% reduction in ferritin protein expression
compared to that of the age matched iron overload value (Figure 13).

Figure 13. Western blot analysis of ferritin heavy chain (ferH) protein expression
in hepatic tissue of gerbils in the experimental groups. Effects of iron overload and
deferasirox treatment on ferritin protein expression were analyzed. Results were
obtained from six experiments and expressed as a percentage of the corresponding age
matched control value (upper panel). Representative Western blot (lower panel). 1m: 1
month interval, 3m: 3 months interval. (*) indicates significant difference from control, (†)
indicates significant difference from iron overload group (P < 0.05)
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Superoxide abundance
Liver specimens were evaluated for ·O2- generation within tissue sections
utilizing HE fluorescence.

Iron overload induced a 167.0% increase in fluorescent

staining in hepatic tissue three months after iron injections (P < 0.05). This increase was
reduced by 48.6% with deferasirox treatment in hepatic tissue when compared to agematched control (P < 0.05) (Figure 14).
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Figure 14. Detection of hepatic superoxide by hydroethidine in Ctrl, IO, and
IO+DFR. The increase in superoxide involves all regions of the hepatic plate (Upper
panel). Quantification of hepatic superoxide as determined by intensity of
fluorescent ethidium bromide-stained nuclei (Lower panel). 3m: 3 months interval.
An asterisk (*) indicates significant difference from control animals, (†) indicates
significant difference from iron overload (P < 0.05).
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Protein oxidation
Iron catalyzed oxidation of proteins introduces carbonyl groups at lysine,
arginine, proline, and threonine residues in a site specific manner. Protein modification
by oxygen free radicals and other reactive species were analyzed in hepatic cells from
control, iron overloaded, and deferasirox treated groups utilizing an OxyBlot™ detection
kit. Interestingly, iron overload induced 1.6 fold increase in protein oxidation at 3
months. Protein oxidation was reduced by 50.2% after three months of deferasirox
treatment (P < 0.05) (Figure 15).

Figure 15. Effect of iron overload or deferasirox treatment on hepatic protein
carbonylation. (Left) Representative oxy-blots of hepatic protein isolates from Ctrl, IO,
and IO+DFR. (Right) Quantification of oxidatively modified proteins in hepatic protein
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isolates obtained from the corresponding groups. 3m: 3 months interval. An asterisk (*)
indicates significant difference from control animals, (†) indicates significant difference
from iron overloaded animals (P < 0.05).

Cell death
To investigate whether iron overload induced alterations in oxidative stress are
related to hepatic cell death, we examined the number of nuclei staining positively for
DNA fragmentation by TUNEL assay. The apoptotic index in the hepatocytes of iron
overloaded gerbils increased 7.5 fold compared to age-matched control 3 months post
iron overload, while deferasirox treatment demonstrated a 41.0% reduction in the
apoptotic index when compared to this iron overload induced increase (P < 0.05)
(Figure 16).
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Figure 16. Representative cross sections showing the changes in nuclei
exhibiting DNA strand breakage as determined by TUNEL staining in Ctrl, IO, and
IO +DFR. Bar = 50 µm (upper panel). Quantification of hepatic apoptotic cells as
determined by the number of TUNEL positive cells by the number of DAPI positive cells
per mm2, apoptotic index, (Lower panel). 3m: 3 months interval. An asterisk (*) indicates
significant difference from control animals, (†) indicates significant difference from iron
overload (P < 0.05).
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Bcl-2 apoptotic signaling
The expression of the anti-apoptotic (Bcl-2) and the pro-apoptotic (Bax and Bad)
proteins and the ratio of Bax to Bcl-2 were evaluated by western blotting. When Bax is
in excess, Bcl-2 cannot bind and sequester all the Bax protein, thus allowing Bax to
oligomerize and act on the mitochondrial membrane to cause release of cytochrome c
from the inter-membrane space to the cytosolic space. Thus a higher Bax to Bcl-2 ratio
would potentially increase the susceptibility to mitochondrial permeability. We
investigated if there were any changes in the anti-apoptotic (Bcl-2) and pro-apoptotic
(Bax and Bad) proteins in the experimental groups. The expression of Bax/Bcl-2 was
62.1% higher than control after 10 weeks of iron loading (P < 0.05) (Figure 17). Bax/Bcl2 levels remained consistently elevated and were 52% and 121% higher after 1- and 3months follow up compared to respective age matched controls (P < 0.05) (Figure 17).
We demonstrated decreased levels of Bax/Bcl-2 expression with deferasirox treatment
and it was 21.7% and 47% lower after 1- and 3-months of treatment, respectively (P <
0.05) (Figure 17).
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Figure 17. Effects of iron overload and deferasirox treatment on Bax/Bcl-2 protein
level in hepatic tissue of gerbils in the experimental groups. Results were obtained
from six experiments and expressed as a percentage of the corresponding age matched
control value (upper panel). Representative Western blot (lower panel). 1 m = 1 month
interval, 3 m = 3 months interval. (*) indicates significant difference from control, (†)
indicates significant difference from iron overload group (P < 0.05).

In addition, Bad expression was 73%, 52%, and 77% higher in the IO, 1 monthIO and 3 months-IO, respectively (P < 0.05). With three months of deferasirox treatment
Bad expression was reduced by 33% compared to age matched iron overload group (P
< 0.05) (Figure 18).
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Figure 18. Effects of iron overload and deferasirox treatment on Bad protein level
in hepatic tissue of gerbils in the experimental groups. Results are obtained from
six experiments in each group and expressed as a percentage of the corresponding age
matched control value (upper panel). Representative Western blot (lower panel). 1 m =
1 month interval, 3 m = 3 months interval. (*) indicates significant difference from
control, (†) indicates significant difference from iron overload group (P < 0.05).

Caspase-3 activation
One critical step in the execution of the apoptotic program that elicits DNA
fragmentation is cleavage of caspase-3 into 19- and 17-kDa fragments. Caspases are
cysteine dependent aspartate specific proteases which activate endonucleases integral
in the final execution of nuclei and cell death. Cleaved caspase-3 is downstream of the
Bcl-2 family apoptotic cascade and integrates apoptotic signaling from the cytokine/Fas
and Ca2+/ER pathways as well. Caspase-3 activation, as measured by cleaved
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caspase-3 fragment level, was markedly higher in the iron overload liver (86%, and
102% after 1 and 3 month of follow up, respectively) as compared to age matched
control liver (P < 0.05) (Figure 19). We demonstrated a significant reduction of cleaved
caspase-3 by 21% in the 3 months deferasirox treatment group (P < 0.05) (Figure 9).
No significant difference in the expression of the full length caspase-3 was observed
between groups.

Figure 19. Effects of iron overload and deferasirox treatment on full length and
cleaved caspase-3 in hepatic tissue of gerbils in the experimental groups. Results
were obtained from six experiments and expressed as a percentage of the
corresponding age matched control value (upper panel). Representative Western blot
(lower panel). 1 m = 1 month interval, 3 m = 3 months interval. (*) indicates significant
difference from control, (†) indicates significant difference from iron overload group (P <
0.05).
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Table 6. Regression analysis of the relationship between expression levels of
specific proteins and TUNEL, HE staining intensity, liver weight, and hepatic iron
levels obtained from experimental groups

Liver wt

Iron

Ferritin

Oxyblot

HE

TUNEL

Liver wt

N.T.

0.693†

0.703††

0.513†

0.511†

0.562†

Iron

0.693†

N.T.

0.957†††

0.911†††

0.919†††

0.949†††

Ferritin

0.703††

0.957†††

N.T.

0.922†††

0.935†††

0.927†††

Oxyblot

0.513†

0.911†††

0.922†††

N.T.

0.922†††

0.852††

HE

0.511†

0.919†††

0.935†††

0.922†††

N.T.

0.869††

TUNEL

0.562†

0.949†††

0.927†††

0.852††

0.869††

N.T.

Bax

0.427*

0.661†

0.696†

0.550†

0.535†

0.341*

Bcl-2

0.135

0.299

0.321*

0.329*

0.272

0.111

Bad

0.127

0.127

0.138

0.583†

0.575†

0.362*

0.424*

0.637†

0.659†

0.846††

0.824††

0.689†

Independent
variables

Apoptotic
regulators

Caspase-3
(cleaved)

(†††) indicates very high correlation, (††) indicates high correlation, (†) indicates moderate correlation,
(*)indicates low correlation, N.T. = not tested.

Discussion
The iron overloaded gerbil, a well accepted animal model of iron overload, is
thought to closely resemble many of the effects of iron overload seen in humans
(Carthew, Dorman et al. 1993; Yang, Brittenham et al. 2003). Using the gerbil model of
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iron overload, we have previously demonstrated that deferasirox treatment removes
cardiac iron and reduces the iron associated increase in oxidative stress and ferritin
expression (Al-Rousan, Paturi et al. 2009). Similar to our finding in the heart, here we
demonstrate that iron overload caused hepatic iron deposition and lipid accumulation
and resulted in a dramatic increase in hepatic iron content. This elevated level of iron
deposition was also associated with increased ferritin protein expression, elevated
levels of ROS, and cell death signals. Iron chelation by deferasirox reduced iron
deposition and the induction of ferritin and Bax proteins, whose gene expression is
thought to be linked to oxidative stress, suppressed iron overload-induced superoxide
formation and protein oxidation, and reduced the incidence of hepatocyte death. These
data collectively suggest that deferasirox may afford hepatic protection against ironinduced pathogenesis.

Deferasirox decreases hepatic iron and ferritin levels in the iron-overloaded gerbil
We found that hepatic iron levels after three months of follow up were
significantly lower than observed in the 10-week iron overload animals (P < 0.05).
These observations are consistent with the findings by Wood et al. (Wood, Otto-Duessel
et al. 2006) that body iron levels exhibit spontaneous (non chelator-mediated)
redistribution and elimination. These levels, however, remained elevated and potentially
harmful to hepatic tissue. Three months of deferasirox treatment significantly reduced
hepatic iron content by 43.5% compared to that of the age-matched iron overloaded
group (P < 0.05) (Figure 11). As expected from its predominantly biliary elimination
clearance

(Hershko, Konijn et al. 2001), these iron removal data suggest that

deferasirox appears to be particularly efficient for hepatocyte clearance. Similar to our
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biochemical assessment, the findings from our histological data suggest that deferasirox
is efficacious in removing liver iron. In addition, we also observed evidence of lipid
accumulation in the iron-overloaded liver (Figure 12, B arrows). Elevated free iron has
been shown to be hepatotoxic, possibly exerting its effects by interfering with
mitochondrial or microsomal function which disrupts lipoprotein transport and fatty acids
homeostasis (Baptista-Gonzalez, Chavez-Tapia et al. 2008; Duncan 2008; RaszejaWyszomirska, Lawniczak et al. 2008). Interestingly, with deferasirox treatment we failed
to find any evidence of fatty acid accumulation suggesting perhaps that this agent is
efficacious in preventing iron-induced liver damage. More research to specifically
address hepatic mitochondrial function in these groups will no doubt be useful in
furthering our understanding the effect of deferasirox on liver physiology.
It is well accepted that ferritin is the principal storage protein for iron (Arosio and
Levi 2002). The increase in ferritin expression in response to iron overload is thought to
provide a cytoprotective mechanism against iron induced toxicity (Balla, Jacob et al.
1992; de Valk and Marx 1999). Nonetheless, it should be noted that although ferritin
and hemosiderin have traditionally been regarded as ‘safe’ storage forms of iron, this
does not mean that the iron contained in these molecules cannot potentiate the
development of oxidative stress under certain conditions. Indeed, it has been recently
demonstrated that the superoxide radical is capable of mobilizing iron from ferritin and
that this can result in the production of iron-catalyzed hydroxyl radicals (Bartfay,
Dawood et al. 1999).
The synthesis of ferritin is tightly regulated and is dependent on intracellular iron
levels. When iron is low, binding of the iron-regulatory proteins (IRP-1) to ironresponsive elements (IRE) inhibits translation of ferritin. Conversely, when cellular iron
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is high, the opposite regulation takes place (Ferrara and Taylor 2005). In the present
study, we demonstrated a significant increase in ferritin levels with iron loading and
more importantly, that these elevations were significantly suppressed with deferasirox
treatment (Figure 13). These results are in agreement with previous findings that
chelation therapy with deferoxamine reduced iron-induced ferritin upregulation in rat
aorta (Ishizaka, Saito et al. 2005). To our knowledge, the present study is the first
description of the effect of iron overload and deferasirox treatment on hepatic ferritin
expression.
It is thought that deferasirox does not chelate tightly bound iron stores (eg,
hemoglobin or the cytochromes), but instead extracts iron from storage proteins such as
ferritin with relatively weak bonds (Evens, Mehta et al. 2004). On the other hand, in vitro
studies have shown that deferasirox is able to access the intracellular labile iron pool
(LIP) (Glickstein, El et al. 2005; Glickstein, El et al. 2006). It is important to note here
that ferritin-bound iron is in an equilibrium state with the free iron in the LIP (Crichton
and Ward 2003). Thus, it is plausible to postulate that deferasirox may indirectly reduce
ferritin bound iron by shifting the equilibrium in favor of the more accessible iron in the
LIP.

Reduced hepatic iron levels are associated with decreases in tissue ROS
Because humans have no physiologic means of eliminating excess iron, any
persistent increase in intake may eventually result in iron overload. When the extent of
iron accumulation exceeds the body's ability to safely sequester the surplus iron, free
iron builds up in the LIP (Breuer, Epsztejn et al. 1996). Normally, the LIP represents
only 3–5% of the total cellular iron (Arosio and Levi 2002). Iron overload can induce
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about a three-fold increase in the iron level in hepatic LIP, which triggers oxidative
stress and cell injury (Arosio and Levi 2002).
The formation of highly toxic hydroxyl radical via Fenton and Haber-Weiss
reactions, followed by the subsequent formation of lipid peroxidation products, is
postulated to be an underlying mechanism of iron mediated liver injury (Britton and
Bacon 1994; Staubli and Boelsterli 1998). In the liver, iron overload is thought to
damage the hepatocytes and dysregulate a variety of metabolic pathways, which if
allowed to proceed unchecked could eventually result in liver fibrosis, cirrhosis, or other
liver diseases (Ramm and Ruddell 2005; Tsukada, Parsons et al. 2006). Iron chelators
decrease the redox activity of iron through their ability to form complexes with Fe (III),
preventing the reduction of Fe(III) by superoxide to the reactive Fe(II) state.
In the present study, we showed that ROS levels as superoxide anion (O2•– )
were increased in the iron-overloaded hepatic tissue as determined by hydroethidium
staining (Figure 14). These findings are consistent with earlier data which have
suggested that increased iron levels are associated with increases in liver ROS
(Glickstein, El et al. 2006; Pardo Andreu, Inada et al. 2008). Possible sources of
increased ROS with iron loading are not fully elucidated but could include the iron
catalyzed Fenton-Haber Weiss reaction, redox cycling, and possibly iron associated
changes in NADPH oxidoreductases and mitochondrial function (MacCarthy, Grieve et
al. 2001; Galaris and Pantopoulos 2008; Kim, Kim et al. 2008; Pardo Andreu, Inada et
al. 2008). Whether these changes in ROS are directly related to the improvements in
histological appearance we observe with deferasirox treatment are not fully elucidated.
Our data suggested that iron overload was associated with increased levels of
protein oxidation in the liver (Figure 15) and importantly, that deferasirox treatment is
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capable of decreasing the amount of oxidized proteins in the iron overloaded liver.
Although the physiological effects of protein oxidation in the liver are not entirely
elucidated, recent work has suggested that protein oxidation can alter hepatic enzyme
activity. For example, the increased oxidative levels have been shown to alter the
activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR), the rate
limiting enzyme in the production of cholesterol (Pallottini, Martini et al. 2005). Whether
the proteins identified in our analysis are related to hepatic metabolism is unknown and
will necessitate further experimentation. Nonetheless, the decreases we see in the
quantity of modified proteins and liver ROS levels are highly correlated with deferasiroxassociated improvements in liver iron levels and liver histology (Table 6). Taken
together, these data suggest that deferasirox may be efficacious in preventing iron
accumulation, ROS accumulation and iron-overload induced liver pathology.

Reduced hepatic iron levels are associated with decreases in iron-associated cell death
A link between oxidative stress and cell death has been reported in several
conditions including hemochromatosis (Cooksey, Jouihan et al. 2004), alcoholic liver
disease (Zima and Kalousova 2005), hepatitis, and liver cirrhosis (Kaplowitz 2000).
However, the mechanism by which free radicals can induce cell death is not well
understood. Here, we demonstrated that iron overload was associated with increased
hepatic cell death as determined by increased incidence of TUNEL reactive nuclei
(Figure 16). Interestingly, the number of TUNEL positive nuclei was significantly
reduced with deferasirox treatment.
To investigate the mechanism of iron overload-related DNA strand breakage that
we observed in our TUNEL studies, we examined the expression of Bcl-2 family
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proteins. It is thought that the ratio of Bax to Bcl-2 plays an important role in regulating
the release of cytochrome-c from the mitochondria into the cytosol. This latter effect is
favored as the balance shifts toward Bax leading to cell death (Oltvai, Milliman et al.
1993). In iron overloaded animals, we found that Bax expression was elevated and that
these levels were reduced with deferasirox treatment (Figure 17). To expand upon this
finding we also examined the regulation of Bad, a pro-apoptotic member of the Bcl-2
family that can displace Bax binding from Bcl-2 and Bcl-XL, resulting in cell death
(Hengartner 2000). Similar to our findings with Bax, deferasirox treatment significantly
decreased the expression of Bad (Figure 18).
Caspase-3 is a key effector of mitochondrial-mediated apoptosis (Cai, Yang et
al. 1998; Porter and Janicke 1999; Goldspink 2003) that is normally activated by
proteolytic cleavage (Cohen 1997). To investigate whether alterations in the regulation
of caspase-3 may be involved, here we examined the expression of caspase-3 with iron
overload and deferasirox treatment. With iron overload, we observed increases in the
amount of cleaved caspase-3 (Figure 19). Further, we demonstrated that deferasirox
administration decreased caspase-3 cleavage. These data, in conjunction with our
findings that deferasirox alters the regulation of Bcl-2, Bax and Bad, suggest that
deferasirox may decrease iron-induced apoptosis by affecting the regulation of the
mitochondrial apoptotic cascade. This is in agreement with the results of other recent
investigations that have implicated increased iron levels as causing mitochondrial
dysfunction and apoptosis (Eaton and Qian 2002; Walter, Knutson et al. 2002). Whether
the activation of the mitochondrial apoptotic pathway is dependent upon iron-associated
increases in ROS per se, or ROS acting in concert with other factors, is worthy of
detailed studies.
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Conclusions
In conclusion, our data suggest that iron overload is associated with increases in
hepatic iron levels, indices of ROS, and increased hepatic apoptosis and that
deferasirox is efficacious in attenuating these parameters. Given that iron overload is
associated with an increased risk of developing liver fibrosis, decreased hepatic
function, and hepatic cancer (Bonkovsky and Lambrecht 2000; Fattovich, Stroffolini et
al. 2004) it is likely that deferasirox treatment may find a use for the treatment and / or
prevention of several hepatic disorders.
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Article #3: Corresponds to Specific Aim #3
To determine the long term cardiovascular complications associated with iron
overload and to determine if chronic deferasirox administration is able to
prevent/reduce

these

complications,

remodeling and functional abnormalities.
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Abstract
Iron-induced cardiovascular disease is the leading cause of death in ironoverload patients. Deferasirox is a novel tridentate oral chelator that exhibits a half-life
suitable for once-daily dosing; however, little is known regarding the effectiveness of
this agent in preventing iron-induced cardiovascular dysfunction. Adult male Mongolian
Gerbils were randomly divided into three groups: control, iron overload, and iron
overload followed by deferasirox treatment. Iron overload animals received iron-dextran
100 mg/kg i.p /5 d for 10 wks while deferasirox was given 100 mg/kg/d p.o for 9 months
post iron loading. Cardiac and aortic iron levels were determined by inductively coupled
plasma atomic emission spectrometry.

Gerbil EKG (standard leads I, II, & III) and

echocardiograms (Philips Sonos 5500) were obtained in anesthetized animals at regular
intervals. Compared to control animals, iron concentration was 3.3 and 2.4 fold higher in
iron overloaded heart and aorta respectively (P < 0.05). Deferasirox treatment reduced
cardiac and aortic iron levels by 31.6%, and 34.6%, respectively (P < 0.05). These
results were consistent with the decrease in cellular iron deposition observed with
Prussian blue iron staining. Cardiac mass/body wt ratio was increased by 34% in the
iron overloaded group and was 24% lower with deferasirox treatment. Iron overloaded
gerbils were found to exhibit frequent arrhythmias including premature ventricular
tachycardia (6/10), supraventricular tachycardia (3/10), recurrent ventricular tachycardia
(4/10), and increased mortality (3/10) with the latter occurring most likely due to fatal
arrhythmias. Echocardiographic assessment demonstrated iron-induced increases in
LVPWd, LVIDd, and LVSd by 48.6%, 26.2%, and 42.4%, respectively (P < 0.05).
Similarly, ejection fraction and fractional shortening were reduced by 29.6% and 22.9%
compared to controls (P < 0.05). Deferasirox reduced the incidence of iron-induced
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arrhythmia and either prevented or significantly decreased iron-induced changes in
cardiac structure (LVIDd: 23.6%; P < 0.05), LVPWd (21.5%; P < 0.05), LVSd (27.2%; P
< 0.05) and function (EF: 29.8%; P < 0.05), (FS: 27.8%; P < 0.05). Taken together,
these data suggest that once daily oral deferasirox treatment appears to be effective in
preventing or reducing iron-induced cardiovascular abnormalities.

Introduction
Despite dramatic improvements in care, iron induced cardiac disease remains
the most frequent cause of death in thalassemia major and a major life-limiting
complication of other transfusion-dependent patients, hereditary hemochromatosis, and
other forms of iron overload (Neufeld 2006). The most common form of cardiac
hemosiderotic injury is dilated cardiomyopathy, generally manifesting as systolic or
diastolic dysfunction (Liu and Olivieri 1994). Signs of myocardial damage due to iron
overload include arrhythmia, angina, cardiomegaly, heart failure, and pericarditis. Iron
overload can also produce conduction defects secondary to iron deposition in the
Bundle of His and the Purkinje system (Schwartz, Li et al. 2002). Sudden death due to
arrhythmia can therefore occur among patients with advanced iron overload (Klintschar
and Stiller 2004). Although prophylactic therapy with angiotensin converting enzyme
inhibitors and β-blockers can help reduce cardiac morbidity and mortality (Trad,
Hamdan et al. 2009), the mainstay of therapy for cardiac iron overload remains iron
chelating agents. The goal of chelation therapy is primarily the prevention of iron
overload in order to preserve organ function and improve patient survivability. To date,
only deferoxamine is globally available for the first-line treatment of transfusion-related
iron overload. Effective chelation with deferoxamine has been shown to increase
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survival rate and prolong length and quality of life for transfusion patients (Obejero-Paz,
Yang et al. 2003). However, deferoxamine chelation therapy is associated with a
cumbersome treatment regimen and toxic side effects resulting in low patient
adherence. In addition, treatment with deferoxamine has limited clinical outcomes and
some patients still die of iron-induced cardiac disease despite apparently adequate liver
iron chelation.

Unlike deferoxamine, deferasirox is an orally effective once daily iron chelating
agent with favorable patient satisfaction (Neufeld 2006; Cappellini and Pattoneri 2009).
Deferasirox was recently approved by the Food and Drug Administration (FDA) and is
the first oral medication approved in the United States for this purpose (Lindsey and
Olin 2007; Stumpf 2007). As deferasirox is well tolerated, it is expected to greatly
enhance the acceptance of iron chelation therapy and offer a new alternative to
burdensome continuous infusion therapy (Stumpf 2007). Whether deferasirox is
efficacious in preventing the cardiovascular complications associated with iron overload
is not yet clear. To address this gap in our understanding, we examined if the chronic
administration of deferasirox is capable of removing excess iron from heart and other
tissues, and whether it is capable of preventing or reducing the severity of iron-induced
cardiac complications in the iron overloaded gerbil, a well accepted animal model of iron
overload that is thought to closely resemble the effects of iron overload seen in humans
(Carthew, Dorman et al. 1993).

Our data suggest that once daily oral deferasirox

treatment appears to be effective in preventing or reducing iron-induced cardiovascular
abnormalities.
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Results
Characterization of animals
Total body and heart weights were obtained and compared. All animals tolerated
the iron loading and chelation without any apparent ill effects. The body weights of iron
overloaded gerbils were similar to controls, indicating that the injection of iron dextran
did not result in debilitation or weight loss. Cardiac, hepatic and kidney weights were
increased 34%, 41.4% and 30.9% (P < 0.05), respectively, in the iron overloaded group,
and deferasirox treatment was effective in reducing iron-associated increases in whole
tissue weight by 23.9%, 16.3%, 23.7% (Table 7).

Table 7. Average heart, liver, and Kidney weights of gerbils in the experimental
groups followed for 9 months
Group
n = 10/ group

Heart/body wt (%)

Liver/body wt (%)

Kidney/body wt (%)

Ctrl

0.39 ± 0.01

4.1 ± 0.31

0.81 ± 0.02

IO

0.52 ± 0.02*

5.8 ± 0.30*

1.05 ± 0.03*

IO + DFR

0.40 ± 0.01†

4.9 ± 0.34†

0.8 ± 0.02†

An asterisk (*) or cross (+) indicates significant difference from age matched control and iron overloaded
groups, respectively.

Cardiac, aortic, and hepatic iron levels
Compared to hearts obtained from control animals, iron concentration was 3.3
fold higher in iron overloaded hearts (P < 0.05). Deferasirox treatment for 9 months
resulted in a 31.6% decrease in cardiac iron level (P < 0.05) (Figure 20, A). Aortic iron
concentration was 2.4 fold higher in the iron overloaded group compared to controls (P
< 0.05). Nine months of deferasirox treatment decreased aortic iron level by 34.6% (P <
0.05) (Figure 20, B). Similarly, hepatic iron concentration was 49.5 fold higher than that
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of control after nine months of follow up after iron overload. Hepatic iron concentration
was 47.4% lower after 9 months of deferasirox treatment compared to that observed in
the untreated iron overloaded animals. Prussian Blue iron staining of the left ventricle
from the iron overloaded group indicates an increase in iron deposition and tissue
damage compared to that of control. In sections of the left ventricular sections obtained
from deferasirox treated animals, a lower iron deposition and preservation of tissue
morphology was observed (Figure 21).
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Figure 20. Average iron levels in mg/g tissue weight in cardiac (A), aortic (B), and
hepatic (C) tissue of gerbils in the experimental groups followed for 9 months.
Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by deferasirox
treatment. (*) indicates significant difference from control, (†) indicates significant
difference from iron overload group.
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Figure 21. Histological analysis of cardiac tissue of Ctrl (A), IO (B), and IO+DFR
(C) gerbils followed for 9 months. Ferric iron was detected by Prussian blue staining.
No apparent iron deposition was observed in control gerbils. Iron overload resulted in
morphological alteration and iron accumulation in the interstitium and in cardiac
myocytes. Deferasirox treatment preserved tissue morphology and diminished iron
deposition. Bar represents 100 µm; images were taken at 400X original magnification.

Electrocardiographic evaluation
Electrocardiographic measurements suggested an increased incidence of
arrhythmias with iron overload (Figure 22). Iron overloaded gerbils were found to exhibit
frequent premature ventricular tachycardia, (PVC) (6/10), supraventricular tachycardia,
(SVT) (3/10), recurrent sustained and non sustained ventricular tachycardia, (VT)
(4/10), and increased incidence of death (3/10) with the latter occurring most likely due
to fatal arrhythmias (Figure 23). In addition, we observed an increased incidence of
bundle branch block, (BBB) (6/10), negative P wave (8/10), and T wave flattening (5/10)
(Figure 23).
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Figure 22. Representative ECGs (standard leads I, II, III) from control, iron
overload, and deferasirox (DFR) treated groups followed for 9 months. EKG trace
from iron overloaded animal (middle) exhibits ventricular tachycardia, EKG trace from
control (left) and deferasirox treated animal (right) exhibit normal rhythm.
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Figure 23. Frequency of electrocardiographic abnormalities observed in Ctrl, IO,
and IO+ DFR followed for 9 months. PVC = premature ventricular tachycardia, SVT =
supraventricular tachycardia, VT = ventricular tachycardia, BBB = bundle branch block,
p = p wave, T = T wave.

Echocardiographic evaluation (cardiac structure)
Alterations

in

cardiac

structure

were

evaluated

by

echocardiographic

measurements. Our data demonstrated that LVPWd increased by 39.1% and 48.6% in
the iron overloaded group after 6 and 9 months of follow up, respectively (P < 0.05)
(Figure 24). LVPWd was 21.4% and 21.5% lower after 6, and 9 months of follow up,
respectively, with deferasirox treatment (P < 0.05) (Figures 24, 25). Similarly, LVIDd
increased by 18.5%, and 26.2% in the iron overloaded animals after 6, and 9 months of
follow up, respectively (P < 0.05) (Figure 24). In the deferasirox treatment group, LVIDd
was 16.5% and 23.6% lower after 6 and 9 months of follow up, respectively than that
observed with iron overload (P < 0.05). In addition, LVSd was 31.5% and 42.4% higher
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in the iron overloaded group after 6 and 9 months of follow up, respectively compared to
control (P < 0.05). These levels were lower by 23.4% and 27.2% with 6 and 9 months of
deferasirox treatment, respectively (P < 0.05) (Figure 24).
Alterations

in

cardiac

structure

were

evaluated

by

echocardiographic

measurements. Our data demonstrated that LVPWd was increased by 39.1% and
48.6% in the iron overloaded group after 6 and 9 months of follow up, respectively (P<
0.05) (Figure 24). LVPWd was 21.4% and 21.5% lower after 6, and 9 months of follow
up, respectively, with deferasirox treatment (P < 0.05) (Figures 24, 25). Similarly, LVSd
was 31.5% and 42.4% higher in the iron overloaded group after 6 and 9 months of
follow up, respectively compared to control (P < 0.05). These levels were lower by
23.4% and 27.2% with 6 and 9 months of deferasirox treatment, respectively (P < 0.05)
(Figure 24).

-106-

LVPWd (cm)

Ctrl
IO
IO+DFR

0.2
0.18
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0

BL

1 mo

3 mo

BL

1 mo

3 mo

BL

1 mo

3 mo

6 mo

9 mo

0.70

LVIDd (cm)

0.60
0.50
0.40
0.30
0.20
0.10
0.00

6 mo

9 mo

0.18
0.16

LVSd (cm)

0.14
0.12
0.1
0.08
0.06
0.04
0.02
0

6 mo

9 mo

Figure 24. Effect of iron overload and deferasirox treatment on left ventricular
dimension. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by
deferasirox treatment. BL = baseline (before iron loading), mo = months of follow up.
LVPWd = left ventricular posterior wall dimension during diastole, LVIDd = left
ventricular internal wall dimension during diastole, LVSd = left ventricular septal
dimension during diastole
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Figure 25. Representative M-mode echocardiograms from Ctrl (A), IO (B), and IO+
DFR (C) groups followed for 9 months. Arrows indicate left ventricular posterior wall
dimension (LVPW) and is 0.127 cm, 0.153 cm, and 0.136 cm in A, B, and C
respectively.

Echocardiographic evaluation (cardiac function)
Cardiac systolic and diastolic function was evaluated by echocardiographic
measurements. Compared to control, ejection fraction was reduced by 22%, and 29.6%
in the iron overloaded group after 6, and 9 months of follow up, respectively (P < 0.05)
(Figure 26). Similarly, fractional shortening was 12.9% and 29.9% lower than control
after 6, and 9 months of follow up, respectively (P < 0.05) (Figure 26).
Iron-induced decreases in ejection fraction were 17.7% and 29.8% higher than
iron overload group after 6 and 9 months of deferasirox treatment, respectively (P <
0.05) (Figure 26). Likewise, iron induced alteration in fractional shortening were 10%
and 27.8% higher than iron overload group after 6 and 9 months of deferasirox
treatment (P < 0.05) (Figure 26). In addition, gerbils in the iron overloaded group
exhibited a higher frequency of regurgitation of all three cardiac valves (mitral 6/10,
tricuspid 6/10, and aortic 3/10) (Figure 27).
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Figure 26. Effect of iron overload and deferasirox treatment on left ventricular
ejection fraction (EF), and fractional shortening (FS) in gerbils from experimental
groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by deferasirox
treatment. BL = baseline (before iron loading), mo = months of follow up.
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Figure 27. Frequency of cardiac valvular regurgitations observed in Ctrl, IO,
IO+ DFR followed for 9 months. MR = mitral valve regurgitation, TR = tricuspid
valve regurgitation, AR = Aortic valve regurgitation.
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Figure 28. Correlation between cardiac iron concentration and heart/body wt, or
echocardiographic parameters. LVPWd = left ventricular posterior wall dimension
during diastole, LVIDd = left ventricular internal wall dimension during diastole, LVSd =
left ventricular septal dimension during diastole, EF = ejection fraction, FS = fractional
shortening. R = correlation coefficient.
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Discussion
Here, we examine the efficacy of chronic deferasirox administration in preventing
iron induced cardiac complications in the gerbil model of iron overload. Our data are
consistent with the notion that deferasirox treatment removes cardiac iron and reduces
cardiac damage, remodeling, arrhythmias, and declines in indices of cardiac function
that are typically associated with iron overload.
Deferasirox removes cardiac, aortic, and hepatic iron
Iron distribution in the hearts of iron overloaded gerbils is thought to be similar to
that reported in iron overloaded human hearts (Carthew, Dorman et al. 1993). Our
findings demonstrated that cardiac and aortic iron concentrations nine months post iron
loading were 3.3- and 2.4- fold higher than that of control. Hepatic iron levels were
strikingly higher than that of heart and aorta and were 49.5 fold higher than that of
corresponding control. Chronic deferasirox administration significantly reduced iron
concentrations from these tissues and were 31.6%, 34.6%, and 47.4% lower than iron
overload group in heart, aorta, and liver, respectively (Figures 20, 21). These results are
consistent with previous studies suggesting that deferasirox is effective in cardiac and
hepatic iron removal (Wood, Otto-Duessel et al. 2006; Otto-Duessel, Brewer et al.
2008). Whether the disparity in iron levels that we see among tissues is related to
relative differences in the rate or the mechanism of iron uptake or clearance is not clear.
It has been previously suggested that the liver has especially high efficiency of iron
clearance that is related to membrane potential (de Silva, Askwith et al. 1996). In
addition, it is thought that the rate of iron clearance from the myocardium is six times
slower than that of liver (Oudit, Sun et al. 2004). Nonetheless, as similar findings have
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been observed with deferoxamine treatment (Anderson, Westwood et al. 2004), it is
less likely that these differences are chelator-dependent. Specific mechanisms remain
to be established.
Deferasirox treatment preserves cardiac structure and prevents ventricular remodeling
Iron induced cardiac hypertrophy and ventricular remodeling is a serious long
term complication associated with iron overload (Hahalis, Alexopoulos et al. 2005).
Previous findings have suggested that chelation therapy with deferoxamine helps
prevent iron induced cardiac hypertrophy and failure in the clinic (Pennell, Sutcharitchan
et al. 2008) and in animal studies (Yang, Brittenham et al. 2003). Whether deferasirox
produces a similar effect is not clear. Our findings suggest that iron overload was
associated with increased cardiac mass, and a progressive increase in left ventricular
wall dimensions, which reached significance at six- and nine- months following iron
loading. With chronic deferasirox treatment, both cardiac mass and left ventricular
dimensions tended to be preserved with values similar to that found in the control
animals (Table 7, Figure 24). This is in agreement with recent case reports that have
demonstrated that deferasirox treatment restored cardiac left ventricular diameter, left
ventricular septum thickness, and left ventricular posterior wall dimension (Kiguchi, Ito
et al. 2009) and reversed dilated cardiomyopathy (Kiguchi, Ito et al. 2009; Trad,
Hamdan et al. 2009) in patients with iron overload. The mechanism by which chelation
therapy with deferasirox confers such cardioprotection is not known. We have
previously demonstrated that deferasirox treatment reduced iron induced oxidative
stress and MAPK phosphorylation (Al-Rousan, Paturi et al. 2009), both of which are
thought to be implicated in cardiac hypertrophy. Nevertheless, a causal link between
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oxidative stress, MAPK phosphorylation, and cardiac remodeling, along with the effect
that we see with deferasirox treatment, cannot be established from the current evidence
and will necessitate further experimentation.
Deferasirox treatment preserves cardiac function and reduces incidence of arrhythmia
Without adequate control of iron overload, ongoing cardiac iron accumulation
results in iron deposition in cardiac myocytes and the conduction system, which is
thought to predispose the heart to recurrent arrhythmias and heart failure (Klintschar
and Stiller 2004; Demant, Schmiedel et al. 2007). The mechanism of iron induced
cardiac arrhythmias is not entirely elucidated, but it has been suggested that labile “free”
iron can directly interact and interfere with a variety of ion channels within
cardiomyocytes including L-type calcium channel, the ryonidine sensitive calcium
channel, voltage gated sodium channel, and delayed rectifier potassium channel (Oudit,
Sun et al. 2003; Wood, Enriquez et al. 2005; Oudit, Trivieri et al. 2006). Similar to
findings from previous studies, we demonstrate that iron overload was associated with
increased incidence of arrhythmias including premature ventricular contractions,
supraventricular- and ventricular tachycardia, and frequent bundle branch blocks (Yang,
Dong et al. 2002; Laurita, Chuck et al. 2003). As predicted, chronic deferasirox
treatment was associated with lower incidence of EKG changes, and no evidence of
ventricular tachycardia was observed in treated animals (Figure 23). This is consistent
with previous findings that suggested that deferoxamine treatment prevents EKG
abnormalities in the iron overloaded gerbil (Obejero-Paz, Yang et al. 2003).

How

chelation therapy may produce these effects is not clear. It is thought that iron
accumulation in the bundle of His and Purkinje fibers results in delay or blockage of
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myocardial electrical conduction (Schwartz, Li et al. 2002). Thus, it is likely that
chelating agents, by removing iron accumulated in the conduction system, may improve
electrical conduction and thus reduce the incidence of EKG abnormalities associated
with iron overload. Future experiments designed to directly test this possibility will no
doubt be useful in increasing our understanding of how deferasirox exerts its effects.
Iron overload was also associated with progressive decline in left ventricular
ejection fraction and fractional shortening accompanied with an increase in the
frequency of cardiac valve regurgitation. Deferasirox treatment tended to preserve
cardiac function and only a slight decline in ejection fraction was observed (Figure 26).
Similar findings have been demonstrated by Kiguchi and collegues (Kiguchi, Ito et al.
2009) where deferasirox treatment restored ejection fraction and cardiac functions in a
patient with cardiac iron overload. Whether the abnormalities in cardiac structure and
function we observed are directly related to iron induced toxicity is unknown and will
necessitate further experimentation. Nonetheless, the changes that we see in heart
mass, left ventricular dimension, ejection fraction, and fractional shortening are highly
correlated with cardiac iron concentration (Figures 27, 28). Taken together, these data
suggest that deferasirox may be efficacious in the treatment and / or prevention of ironoverload induced cardiac complications.
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IRON LEVELS IN OTHER TISSUES

Pancreatic iron level
We examined the effect of deferasirox treatment at one and three months on
pancreatic iron concentration in the Mongolian gerbil. Compared to control, iron
concentration was significantly higher in the overloaded animals. Our results
demonstrated 37.9% reduction in pancreatic iron after three months of deferasirox
treatment compared to age matched-untreated group (P < 0.05) (Figure 29). Similar
results have been observed with Prussian Blue iron staining were iron deposition was
increased in the pancreatic tissue of the iron overloaded animals especially in the
parenchyma. Tissue sections from animals treated with deferasirox for three months
exhibited an observable clearance of iron deposits and no apparent iron deposition was
observed in control tissues (Figure 30).
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Figure 29. Average iron levels in mg/g tissue weight in pancreatic
gerbils in the experimental groups. Ctrl: control, IO: Iron overload, IO+
overload followed by deferasirox treatment, 1 m: 1 month interval, 3 m:
interval. (*) indicates significant difference from control, (†) indicates
difference from iron overload group (P < 0.05).

tissue of
DFR: Iron
3 months
significant

Figure 30. Histological analysis of pancreatic tissue of control, iron overload, and
deferasirox treated groups followed for 3 months. Ferric iron was detected by
Prussian blue staining. No apparent iron deposition was observed in control gerbils. Iron
overload resulted in iron accumulation in parenchymal cells and to a lesser extent in
pancreatic β-cells. Deferasirox treatment diminished iron deposition from all regions of
pancreatic tissue. Images were taken at 400X original magnification.
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Kidney iron level
Kidney samples from animals in the experimental groups have been examined
for iron level using ICP-AES technique. Compared to that of the corresponding age
matched control group iron concentration in the iron overloaded groups were 97-, 51-,
and 57- fold higher in IO, 1 month-IO, and 3 months-IO, respectively, (P < 0.05) (Figure
31). No significant reduction in kidney iron levels were observed after 1, or 3 months of
deferasirox treatment.

Figure 31. Average iron levels in mg/g tissue weight in kidney tissue of gerbils in
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload
followed by deferasirox treatment, 1 m: 1 month interval, 3 m: 3 months interval. (*)
indicates significant difference from control. (P < 0.05)
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CHAPTER V
GENERAL DISCUSSION

The primary purpose of the present study was to investigate the effect of
deferasirox treatment on iron overload-related complications with special emphasis on
the heart. To address this purpose, iron overload associated alterations in cardiac and
hepatic mass, iron content, histology, oxidative stress, protein expression, and cardiac
structure and function were assessed in iron overloaded or deferasirox treated gerbils in
comparison to control.
More than a decade ago, Carthew and his colleagues (Carthew, Dorman et al.
1993) introduced the Mongolian gerbil model of iron overload. It duplicated, for the first
time, the structural cardiomyopathy and hepatic dysfunction found clinically in patients
with chronic iron excess. In a series of studies by others (Schwartz, Li et al. 2002; Yang,
Dong et al. 2002) and in our own laboratory (Walker, Epling et al. 2007), the gerbil has
been found to provide an animal model that reproduces many of the essential functional
and structural features of iron-induced liver and heart disease in patients. Tissue iron
levels, however, vary among studies based on the dosing regimen of iron-dextran
administration (Kaiser, Davis et al. 2004). Cardiac and hepatic iron levels measured in
the present study fall within the range of iron levels detailed in other studies that have
used a similar dosing regimen (Wood, Otto-Duessel et al. 2006; Otto-Duessel, Aguilar
et al. 2007). Iron chelation with deferasirox was given at 100mg/kg/day. This dose was
chosen based on an earlier study evaluating the dose-response of deferasirox in the
gerbil model (Wood at al. 2004). The highest dose, 100 mg/kg daily, was shown to
significantly reduce hepatic iron content, while lower doses were not effective. Gerbils
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have a 7.8-fold higher surface area to mass ratio, and corresponding metabolic rate,
than humans. The gerbil deferasirox dose of 100 mg/kg translates to only two-thirds of
the standard human dose (20 mg/kg) when normalized according to body surface area
(Otto-Duessel, Aguilar et al. 2007); this is appropriate given that there is not ongoing
transfusional iron accumulation.

Effect of iron overload and deferasirox treatment on tissue iron concentration
Results from previous studies and from the present investigation indicate that
iron accumulates primarily in the liver and to lower extent in the heart and other tissues.
For example, hepatic iron concentration measured in the present study was
approximately 58 fold higher whereas cardiac iron concentration was only 7.4 fold
higher than age matched control animals after 3 months of follow up. On the other hand,
deferasirox treatment for three months resulted in 43.5% reduction in hepatic iron
whereas cardiac iron was reduced by only 23.5%. It is thought that the mechanisms of
iron uptake and clearance differ in heart and liver tissue, resulting in differing iron
transport kinetics (Schwartz, Li et al. 2002). Previous studies have suggested that
cardiac iron is cleared six-times more slowly than liver iron (Oudit, Sun et al. 2004).
Although not directly examined, this phenomenon may explain why many iron overload
patients develop cardiac dysfunction even though their liver iron levels appear to be
only slightly elevated. As such, there is a need for more research to determine how
elevated liver iron concentrations may correspond to elevations in cardiac iron levels
and an increased risk of possibility of cardiac damage.
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Effect of iron overload and deferasirox treatment on tissue iron distribution
It has been suggested that tissue iron deposition occurs in a non-homogenous
fashion. Similar to previous studies, histological examination of cardiac sections from
iron overloaded gerbils demonstrated that excess iron accumulates primarily in the
cardiomyocytes, cardiac macrophages, and in interstitial spaces of the heart. In patients
with iron overload, it has been reported that iron deposition tends to be more extensive
in the epicardial third of the ventricle, followed by the subendocardium and papillary
muscle, and least in the middle third of the ventricular wall (Walker, Black et al. 2004).
Iron accumulations in the cardiac conduction system, coronary arteries, and valves are
usually limited, but involvement of the conduction system is associated with cardiac
arrhythmias. In the liver, iron deposition tends to be more localized to the periportal
region as opposed to the centrilobular region. Given the high oxygen concentration and
mitochondrial volume in the periportal zone, it has been suggested that iron can be
especially toxic to this particular region of the hepatic plate. Indeed, periportal necrosis
has been described in both humans (Deugnier, Loreal et al. 1992; Hubscher 2003) and
experimental animals (Whittaker, Hines et al. 1996) suffering from hepatic toxicity due to
iron overload. Histological examination of cardiac and hepatic tissue sections from
deferasirox treated gerbils suggest that deferasirox removes iron from cardiomyocytes
and hepatocytes, and perhaps from macrophages, albeit at a much lower rate.

Effect of iron overload and deferasirox treatment on ferritin protein expression
Changes in tissue iron concentration were paralleled by changes in ferritin
protein expression. We demonstrated that ferritin heavy chain levels were 1.6 fold and
2.1 fold higher than control in the iron overloaded heart and liver, respectively, after
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three months of follow up. Similar to our observation with tissue iron clearance,
deferasirox treatment reduced cardiac and hepatic ferritin by 38% and 47.5%,
respectively. The effect of iron chelation therapy on serum ferritin expression is well
documented in the literature as serum ferritin is a common diagnostic tool of body iron
(Perifanis, Christoforidis et al. 2007; Walter, Macklin et al. 2008). However, there is a
limited body of evidence on the effect of iron overload or chelation therapy on ferritin
expression in intact tissue. Only one study has addressed the effect of iron overload on
cellular ferritin expression in vitro (Tran, Eubanks et al. 1997) while one other study
demonstrated that chelation therapy with deferoxamine is associated with reduced ironinduced ferritin upregulation in rat aorta (Ishizaka, Saito et al. 2005). To our knowledge,
the present study is the first description of the effect of iron overload and deferasirox
treatment on cardiac and hepatic ferritin expression.
It is thought that the increase in ferritin expression in response to iron overload
provides a cytoprotective mechanism against iron induced toxicity (de Valk and Marx
1999). Nonetheless, it should be noted that although ferritin and hemosiderin have
traditionally been regarded as ‘safe’ storage forms of iron, this does not mean that the
iron contained in these molecules cannot potentiate the development of oxidative stress
under certain conditions. Indeed, it has been recently demonstrated that the superoxide
radical is capable of mobilizing iron from ferritin and that this can result in the production
of iron-catalyzed hydroxyl radicals (Bartfay, Dawood et al. 1999).
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Effect of iron overload and deferasirox treatment on oxidative stress indices and
apoptosis
While no single mechanism is likely to account for the complex pathophysiology
of iron-induced organ damage, it is believed that iron mediated formation of harmful free
radicals plays a major role (Kell 2009). Indeed, several different investigations have
reported an increase in ROS generation in response to iron overload. For example,
previous studies have demonstrated an increase in aldehyde-derived peroxidation
products in both murine (Bartfay, Dawood et al. 1999), and gerbil models (Otto-Duessel,
Aguilar et al. 2007) of iron overload. In addition, using an oxidative fluorescent dye, Day
and collegues (Day, Duquaine et al. 2003) have suggested an increase in aortic
oxidative stress in the iron overloaded mouse. Here, we demonstrated that iron
overload was associated with an increase in superoxide generation and protein
oxidation in heart and liver. It is thought that metal catalyzed oxidation of proteins
introduces carbonyl groups (aldehydes and ketones) at lysine, arginine, proline or
threonine residues in a site-specific manner (Stadtman 1993). This oxidative
modification can modulate essential biochemical characteristics of proteins such as
enzymatic activity (Oliver, 1987), the DNA binding activity of transcription factors
(Pognonec, Kato et al. 1992), or the susceptibility of proteins to proteolytic degradation
(Wolff and Dean 1986). Although similar findings of reduced ROS with deferasirox have
been found in vitro using cardiac myocytes (Glickstein, El et al. 2006), to our knowledge
this is the first report to demonstrate that deferasirox is capable of reducing ROS in the
intact tissue.
In the present study, the origin of iron-induced increases in superoxide anion was
not investigated. Previous studies have shown that the mitochondria play a primary role
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within the cell both in the handling of iron and in energy production by oxidative
phosphorylation process. Indeed, it is well accepted that mitochondria represent a
primary target of oxidative injury, and thus are the main source for ROS. It has been
shown that ROS are produced through the respiratory chain at a rate which is
dependent on the metabolic state of the mitochondria (Pietrangelo, Montosi et al. 2002).
In the presence of iron ions, ROS give rise to highly-reactive oxidizing species like the
hydroxyl radical (HO•) (Burkitt and Mason 1991; Nunoshiba, Obata et al. 1999). This
increase in oxidizing species in turn may destabilize one or more components of the
electron transport chain that could lead to further ROS accumulation (Bacon, O'Neill et
al. 1993). Experiments designed to assess mitochondrial function with iron overload and
the effects of deferasirox on mitochondrial function will no doubt be useful in examining
this possibility.
How increased iron (or ROS) levels may negatively influence the structure and
function of target tissue is not well understood but recent data suggests that excessive
iron and iron mediated ROS elicit a wide spectrum of responses. These responses
depend upon the severity of the damage, which is further influenced by the cell type, the
magnitude of the dose, and the duration of the exposure. Nonetheless, there are
controversial reports regarding the ultimate physiological outcome of these triggered
responses, ranging from cell survival and adaptation (hypertrophy) to cell death
(apoptosis) (Martindale and Holbrook 2002). In the present investigation, we
demonstrated that iron overload was associated with increased phosphorylation of the
three subfamilies of MAPK: ERK1/2, p38, and JNK. Interestingly, the maximum
phosphorylation signal for p38 and JNK was higher than that observed for ERK1/2. This
result could be justified in the context of p38-MAPK and JNKs being the two principal
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MAPK subfamilies mediating cellular stress signals, whereas the ERKs are primarily
associated with cell growth and proliferation. These results are in agreement with
previous work that suggested increased MAPK phosphorylation associated with ROS
alone (Bhat and Zhang 1999; Park, Yoo et al. 2005) or ROS together with iron overload
(Dai, Huang et al. 2004). In the present report we show that deferasirox treatment
diminishes the extent of iron overload-dependent MAPK phosphorylation. Whether the
induction of MAPK phosphorylation is dependent upon iron excess, ROS, or these
acting in concert with other factors is worthy of detailed studies.
It is thought that the magnitude of ROS plays a role in influencing the particular
course taken by a cell. For example, it has been suggested that intermediate levels of
ROS result in growth arrest whereas severe oxidative stress causes cell death via either
apoptotic or necrotic mechanisms (Martindale and Holbrook 2002). Here we
demonstrated that the increase in hepatic iron concentration together with ROS
accumulation was associated with increased cell death. These results are consistent
with previous findings that suggested that iron overload induced apoptotic cell death in
isolated rat hepatocytes which is thought to be mediated by reactive oxygen species
(Allameh et al. 2008). The increase in cell death as determined by TUNEL was also
associated with an increase in the ratio of Bax/Bcl-2 and Bad expression as well as
caspase-3 cleavage, suggesting the involvement of apoptosis. Although similar findings
have been demonstrated in vitro (Yajun, Hongshan et al. 2005), this is the first report
that describes the effect of iron overload on the apoptotic cascade in intact liver. As
expected, deferasirox treatment was associated with lower cell death signal, Bax/Bcl-2
ratio, Bad expression, and caspase-3 cleavage. These results suggest that apoptosis
may be involved in iron overload induced hepatic toxicity and most importantly, that
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deferasirox may confer protection against these effects. Nonetheless, given the
important role of iron overload in cardiovascular and hepatic disorders, further studies
are required to fully investigate the diversity and multiplicity of interactions between the
signaling cascades involved in their pathogenesis.

Effect of iron overload and deferasirox treatment on cardiac structure and
function
Iron overload is toxic to the heart, and in the syndromes of chronic iron overload
the majority of deaths are due to cardiac failure and sudden death, with the latter
probably due to arrhythmia. In animal studies, a dose relationship between iron load
and the development of cardiac impairment is seen (Carthew, Dorman et al. 1993;
Bartfay, Dawood et al. 1999; Yang, Dong et al. 2002). This wealth of evidence supports
the hypothesis that cardiac complications in iron overload have a direct relationship with
the amount of iron in the heart. Therefore, effective removal of cardiac iron is likely to
reduce the incidence of cardiac complications associated with iron overload. In the
present investigation, cardiac iron levels in the iron overloaded animals were 3.3 fold
that of the control animals and were associated with structural and functional
abnormalities including increased cardiac mass, ventricular remodeling, arrhythmia,
valvular regurgitation, systolic dysfunction, and reduced survival. Chronic deferasirox
administration reduced cardiac iron by 31.6% and this was associated with preserved
cardiac structure and function along with improved survival. These results are in
agreement with previous reports suggesting beneficial effects of chelation therapy with
deferoxamine (Obejero-Paz, Yang et al. 2003; Yang, Brittenham et al. 2003) or
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deferasirox (Kiguchi, Ito et al. 2009; Trad, Hamdan et al. 2009) in preventing/ reversing
iron induced cardiac alterations.
Although cardiac iron deposition, ROS accumulation, and biochemical changes
were evident within a few weeks after iron loading, no significant changes in cardiac
structure or function were observed until 6 and 9 months of follow up.

These

observations resemble the time course of the disorder as described in humans. It has
been reported that cardiac iron toxicity begins to occur after a total of 10 blood
transfusions or approximately 5 g of iron; however, patients may remain asymptomatic
for years. The symptoms of cardiac iron overload normally occur long after the probable
initiation of cardiac iron accumulation with the mean survival falling to a few months
once these complications have arisen (Wood, Enriquez et al. 2005). Intensive iron
chelation therapy may help restore cardiac rhythm and function, which could increase
survival.
It is important to note here that iron deposition is not necessarily the sole cause
of cardiac disease in iron overload conditions. It is well accepted that chronic anemia
itself plays a role in the development of cardiovascular abnormalities regardless of
cardiac iron status (Hahalis, Alexopoulos et al. 2005). For example, thalassemia is
oftentimes associated with elevated cardiac output and stroke volume with the
possibility of systolic dysfunction or severe pulmonary hypertension in advanced stages
of the disease (Bosi, Crepaz et al. 2003). In the present investigation, the effect of the
underlying condition on cardiac health was not examined and cannot be addressed from
the present study design. The development of animal models that better resemble iron
overload in these conditions will no doubt be useful in furthering our understanding of
cardiac pathology in these diseases.
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In conclusion, the work presented here strongly suggests a protective role of
deferasirox against iron induced complications. Evidence from the clinical setting is
needed to confirm these interesting findings and will no doubt be useful in developing
better therapeutic regimens to control iron overload.
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CONCLUSIONS
1.

Deferasirox treatment was found to remove iron from target tissues including
heart, liver, and pancreas. Deferasirox treatment to a similar extent did not
reduce iron accumulated in the kidney or aorta to a significant level.

2.

Iron overload was found to increase the relative expression of ferritin in both
cardiac and hepatic tissue. Deferasirox treatment reduced iron-related
increase in ferritin expression from both tissues.

3.

Deferasirox treatment was found to attenuate oxidative stress indices
observed with iron overload from both cardiac and hepatic tissue. This
includes the ability to reduce cumulative protein oxidation, superoxide
overproduction, and MAPK phosphorylation.

4.

Deferasirox treatment was found to reduce iron overload-related cell death as
well as the relative expression of members of the apoptotic cascade including
Bax/Bcl-2, Bad, and caspase-3.

5.

Long term deferasirox treatment was found to further reduce accumulated
tissue iron from heart, liver, and aorta.

6.

Iron overload was found to profoundly impact cardiac structure and function.
Iron overload was associated with increase heart/body wt, left ventricular
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interior and posterior dimensions, left ventricular septal thickness, frequency
of arrhythmia and valvular regurgitation whereas ejection fraction and
fractional shortening were decreased. Long term deferasirox treatment was
found to preserve both cardiac structure and function.
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FUTURE DIRECTIONS

The present study focused on examining the efficacy of deferasirox treatment in
preventing cardiac complications associated with iron overload. Future investigations
should focus on examining whether deferasirox treatment is protective against other
complications associated with iron overload including, among others, hepatic fibrosis,
hepatocellular carcinoma, and diabetes mellitus.
A critical target of future investigation would also be the assessment of the
efficacy of combination therapy with other chelating agents or antioxidants. Previous
research by Hershko and collegues (2001) have illustrated that the administration of
DFO in combination with deferiprone provides a “shuttling effect” where the smaller and
hydrophilic chelator deferiprone mobilized intracellular iron stores, subsequently
transferring it to intra- or extracellular DFO. Such a strategy was found to enhance iron
excretion and reduce the side effects associated with monotherapy. Whether a
combination therapy of DFO with deferasirox can induce a similar effect is worth
investigating.
Given the fact that oxidative stress is the major contributor to iron-induced
toxicity, it is logical to propose that antioxidants might provide a protective effect.
Recently, Duessel and collegues (Otto-Duessel, Aguilar et al. 2007) have demonstrated
that the administration of the antioxidant taurine improved cardiac indices of oxidative
stress in the iron overloaded gerbil. However, the effect of a combination therapy of
antioxidants with iron chelation therapy is not known. Based on our understanding of the
mechanisms involved in iron-induced toxicity and on previous research suggesting that
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chelating agents improve the efficacy of antioxidants, we propose that the
administration of deferasirox with antioxidants would provide a synergistic effect.
Mitochondria and lysosomes are the major cellular targets of iron mediated
damage. In vitro studies have suggested that deferasirox is able to cross the plasma
membrane and access the cytoplasm. Whether deferasirox possesses accessibility to
subcellular compartments is not known and is worth investigation.
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